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Abstract 
The bioavailability and bioequivalency of oral drug depends on gastrointestinal tract physiology and drug-
related physicochemical and pharmacokinetic factors. In general, bioavailability of a new drug substance or 
new formulation is studied in vivo with healthy volunteers. In vivo bioequivalency studies are needed for 
generic drug products or if a formulation is significantly altered during clinical trials. In certain cases, in 
vitro dissolution studies can be used as a surrogate for in vivo bioavailability or bioequivalency studies, 
referred to as a “biowaiver”. These biowaivers are based either on in vitro-in vivo correlation (IVIVC) or the 
biopharmaceutical classification system (BCS). For drugs with dissolution rate-controlled absorption and 
level A IVIVC, a direct relationship between in vivo drug input and in vitro dissolution may be found. A 
BCS biowaiver can be utilised for BCS I drugs that have complete absorption due to high solubility and high 
permeability.  
In this thesis, in vitro dissolution methods and computer simulation models were developed to predict 
relative bioavailability and bioequivalency and to probe properties of drugs suitable for biowaivers. A level 
A IVIVC model with a stochastic approach was developed for a modified-release formulation series of 
levosimendan. Firstly, the criteria for selection of a dissolution method for the level A IVIVC model were 
evaluated. Secondly, a stochastic Bayesian approach was integrated with the level A IVIVC model in order 
to get a predictions of  concentration-time profiles of different formulations. 
BCS biowaiver studies included literature data evaluation of immediate release formulations of ranitidine, a 
BCS III drug with high solubility and low permeability. Ranitidine was evaluated as a potential BCS 
biowaiver candidate. Generalised rules to estimate the risk of bioinequivalency and to suggest new potential 
biowaivers were evaluated by theoretical pharmacokinetic simulations. Gastrointestinal tract physiology, 
formulation type and drug solubility, dissolution, absorption and elimination rates were taken into account in 
the pharmacokinetic simulation model.  
A dissolution method using pH 5.8 and a rotation speed of 100rpm/min provided acceptable discrimination 
between formulations based on the level B IVIVC and comparisons of pharmacokinetic parameters (MRT 
and Tmax) to the dissolution profiles for levosimendan. The level A IVIVC model with Bayesian approach 
has good external predictability for the formulation series, although an averaged IVIVC model with the same 
data failed. Subject-specific in vivo data was utilised and predictions were obtained as probability 
distributions. The BCS III drug ranitidine was suggested as a biowaiver candidate based on data from the 
literature. Generally, the simulations suggest that BCS III drugs are better biowaiver candidates than some 
BCS I drugs because they have a lower risk of bioinequivalence and they are less sensitive to differences in 
gastric emptying rates and formulation types. BCS I drugs are currently accepted for biowaivers, although a 
short half-life of elimination and rapid rate of absorption cause a high risk of bioinequivalency.  
Pharmacokinetic models were constructed and tested to predict in vitro-in vivo correlations, relative 
bioavailability, risk of bioinequivalency and potential for biowaivers. These models are useful new tools in 
formulation development and regulatory applications.
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Definition of terms 
Bioavailability Bioavailability is defined as the relative fraction of a drug dose that 
enters the systemic circulation  
Bioequivalence Bioequivalence of a drug product is achieved if its extent and rate of 
absorption are not statistically significantly different from those of the 
standard when administered at the same molar dose  
Biowaiver The regulatory acceptance of in vitro testing as a reliable surrogate for 
an in vivo bioequivalence study is commonly referred to as biowaiver  
Level A IVIVC A predictive mathematical model for the relationship between the 
entire in vitro dissolution/release time course and the entire in vivo
response time course, e.g., the time course of drug concentration in 
plasma or amount of drug absorbed 
Input profile In vivo dissolution or in vivo absorption (includes permeability and 
dissolution phases) of the drug from a particular dosage form  
IVIVC A predictive mathematical model describing the relationship between 
an in vitro property of an extended release dosage form (usually the 
rate or extent of drug dissolution or release) and a relevant in vivo
response, e.g., drug concentration in plasma or amount of drug 
absorbed  
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1 Introduction 
After oral administration, drugs are exposed to many physical, chemical and biological 
alterations. To describe and quantify these alterations, the concept of bioavailability has 
been developed. Bioavailability describes the rate and extent to which a drug enters 
systemic circulation after it is administered to a human or animal (Rowland and Tozer, 
1995). The rate and extent of peroral absorption depend firstly on the chemical 
characteristics of the drug (water solubility, lipophilicity, particle size) and secondly on 
formulation variables like excipients and manufacturing procedures. In the early 1960´s, 
an awareness of and concern for bioavailability arose (Barret, 2004). It was observed that 
although two drug products contain the same molar doses of the active ingredient, safety 
and efficacy problems could emerge especially with low therapeutic index drugs like 
digoxin (Rowland and Tozer, 1995). Digoxin immediate-release formulations with 
different drug particle sizes had different bioavailability (Jounela et al. 1975). Differences 
in bioavailability of digoxin, even at the same dosage levels, can lead to one of the two 
extremes: either adverse effects or sub-therapeutic drug concentrations.  
The Food and Drug Administration (FDA) introduced the first regulatory guidance for 
studying bioavailability and bioequivalency of new drug products in 1977. During the 
development of new drugs and drug products, several bioavailability and bioequivalency 
tests should be carried out. Batch size has to be scaled-up, different strengths need to be 
brought to market later on, or post-approval changes to the formulation need to be carried 
out. In all aforementioned cases, bioequivalency studies have typically been used to 
guarantee the therapeutic equivalency of the drug product. All bioavailability and 
bioequivalency studies are time-consuming and expensive, and in vivo studies involve a 
certain risk of adverse reactions among the healthy volunteers.  
To reduce the need for in vivo bioequivalency studies, utilisation of in vitro dissolution 
tests as a surrogate for in vivo bioequivalence studies was introduced with the 
biopharmaceutical classification system (BCS) in 1995 (Amidon and Lennernäs et al., 
1995). Since 1995, some scale-up and post-approval changes have been approved based 
on dissolution tests in the USA (FDA guidance, 1995). In 1997, the FDA published 
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regulatory guidances for in vitro-in vivo correlations (IVIVC), and regulatory authorities 
in Europe followed suit in 2000 (FDA guidance, 1997; EMEA, 2000). These guidelines 
allowed the use of dissolution tests and level A IVIVC models as surrogates for 
bioequivalence studies even when the drug product is significantly altered. In 2000, the 
FDA introduced regulatory guidance for BCS biowaivers (FDA guidance, 2000). The 
BCS biowaiver guidance includes detailed instructions for classification of drugs 
according to the BCS as well as requisites for waiving the bioequivalence studies in the 
case of major product changes or in the development of new generic immediate-release 
drug products. BCS I drugs with complete drug absorption and rapid dissolution were 
considered to be biowaiver candidates. Later, the European regulatory authority, EMEA, 
followed with a set of guidelines of similar principles (EMEA, 2002). IVIVC and BCS 
biowaiver guidelines have a remarkable potential for reducing the number of in vivo
bioequivalence studies. However, fewer biowaiver-based new generic oral drug 
applications have been received than expected (Barends, 2005).  
The World Health Organization (WHO) has actively utilised BCS biowaivers (WHO, 
2006). New, cheap, effective and safe drug products are needed in developing countries. 
The Working Group on the Biopharmaceutical Classification System of the International 
Pharmaceutical Federation (FIP) has produced a series of publications in the Journal of 
Pharmaceutical Sciences. In these publications, the WHO list of essential drugs is 
inspected for new BCS biowaiver candidates. The BCS biowaiver evaluation for ranitidine 
presented in this thesis is part of this series.  
In addition, with regulatory applications IVIVC and BCS biowaivers can be utilised in 
formulation development of new and generic oral drug products. The dissolution method 
can be used to guide formulation development, if a level A IVIVC is found. The selection 
of dissolution method and the utilization of in vivo data are critical steps in the 
development of a level A IVIVC model. The dissolution method should have an 
acceptable discrimination ability, i.e., formulations with statistically significant differences 
in pharmacokinetic parameters should have dissimilar dissolution profiles. The in vitro-in 
vivo relationship is typically determined using averaged in vitro and in vivo data. Many 
drugs have high pharmacokinetic variability and/or only a few subjects are involved in the 
in vivo studies. In these cases especially, development of an IVIVC model may fail if all 
relevant in vivo data cannot be utilised in the model. Subject-specific in vivo data, 
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uncertainty and variability related to the data and level A IVIVC model fitting can be 
described by integrating a stochastic approach into the level A IVIVC model. New criteria 
for selecting the dissolution method and utilisation of a stochastic Bayesian approach in 
level A IVIVC models are presented in this thesis. 
BCS classification of new drug candidates or generic drugs gives information about the 
rate-limiting step for drug absorption, whether solubility or permeability limited. The BCS 
provides a practical first step to estimate oral drug absorption properties. However, the 
BCS system is a simplified approach to the complex absorption process, where 
physiological, physicochemical, drug- and formulation-related variables affect the rate and 
extent of drug absorption. This dynamic process cannot be estimated based on solubility, 
permeability, and dissolution properties. To take into account all variables simultaneously, 
a dynamic pharmacokinetic model is needed. In this thesis, intra- and inter-individual 
variability in gastric emptying, formulation type and drug elimination were taken into 
account for the first time in a pharmacokinetic model to predict bioequivalence of drugs 
and to suggest candidates for BCS biowaivers. BCS III drugs had special interest, because 
they have been suggested as biowaivers in many publications and they not seemed to be 
sensitive to dissolution rate differences, because permeability rate controls absorption 
(Blume and Schug, 1999; Yu et al. 2002; Cheng et al. 2004; Vogelpoel et al. 2004; Polli et 
al., 2004). On the other hand our own hypothesis, that Cmax of part of the BCS I drugs 
were sensitive to dissolution rate differences needed to be verified. 
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2 Literature Review 
2.1 Oral drug absorption 
Most drugs are administered orally, which is a convenient route for the patient. An 
identical drug dose is easy to administer repeatedly and the dosing is not dependent on 
administration technique, e.g. as with pulmonary drug treatment. However, after oral 
administration, the formulation and drug are exposed to a number of physicochemical, 
biopharmaceutical and pharmacokinetic factors before the drug reaches its site of action. 
During the first stage, the drug is released and dissolved from the solid dosage form to the 
gastrointestinal fluids and thereafter, the dissolved and solid drug particles are distributed 
to the gastrointestinal tract. The dissolved drug penetrates through the gut wall into the 
portal vein. Part of the drug may be metabolised in the gut lumen or the efflux proteins in 
the gut wall may efflux the drug back to the intestinal lumen. The drug flows from the 
portal vein to the liver, where first-pass metabolism takes place before the drug begins to 
circulate systemically. Via systemic circulation, the drug is distributed to the peripheral 
tissues and to the site of action. The parent drug and its metabolites are mainly excreted to 
the feces and urine.  
Transport mechanisms in the drug absorption phase
One of the most critical steps in oral absorption is drug penetration through the gut wall. 
Drugs may permeate by passive diffusion or via active ATP dependent transport proteins 
(Fig. 1). Small and lipophilic drug molecules favour passive diffusion via a transcellular 
route, i.e., they permeate through the cell membranes of the enterocytes. Small hydrophilic 
molecules can permeate passively through the paracellular space between the epithelial 
cells. Carrier-mediated transcytosis is involved in transport of some vitamins. 
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Portal vein
1 2a 2b 2c 3
1.  Paracellular passive diffusion
2. Transcellular pathway     
2a.  passive diffusion
2b.  carrier-mediated
2c.  receptor-mediated endocytosis
3.  Carrier-mediated efflux pathway
Gut lumen 
Figure 1 Transport mechanisms of orally administered drugs.  
Active transport mechanisms require specific binding of the drug as a substrate to the 
transporter protein in the cell membrane. There are many different transporters that are 
expressed in the gut lumen, and they can transport chemicals with a variety of molecular 
structures. There are several specific carrier systems for organic cationic and anionic 
molecules, amino acids and peptides. These transporters shuttle compounds from the 
apical side to the basolateral side of enterocytes i.e. from gut lumen towards the portal 
vein. These influx transport systems are involved in absorption of endogenous compounds 
like nutrients and hormones, and xenobiotics like drugs and prodrugs. Efflux proteins 
pump molecules from the apical side to the gut lumen or from the basolateral side to the 
portal vein. They protect organs from exogenes like drugs. The relative importance of 
active and passive permeation depends also on the rate of passive diffusion. Rapid passive 
diffusion may dominate the entire absorption process, and active transport may have a 
minor role. In contrast, peptides have negligible passive diffusion and, therefore, their oral 
absorption is dominated by active transport.  
Saturable processes in the absorption phase
Active transport, both influx and efflux, and metabolism in the intestine can be capacity 
limited (Ritschel and Kearns, 1999). Absorption and metabolism of low doses can obey 
first-order kinetics, but at high doses the transport capacity may be exceeded, and then the 
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system follows Michaelis-Menten kinetics. This leads to nonlinear dose-dependent 
pharmacokinetics, and in addition transporter-related drug-drug interactions may take 
place. A nonlinear absorption phase may cause intra- and/or inter-individual variability in 
drug absorption. Substrates and inhibitors for certain influx and efflux proteins are found 
using in vitro methods like Caco-2 cell culture studies. In the context of transport proteins, 
the determination of in vitro-in vivo relationships is challenging. Different quantities of 
efflux and influx proteins are expressed in Caco-2 cells compared to enterocytes in the gut 
lumen, and functionality of the proteins may differ. Thus quantitative in vivo predictions 
cannot be easily obtained. Interactions can be studied in vivo by administering an inhibitor 
of a certain transport protein. The antitumour drug topotecan was administered with and 
without GF120918, an inhibitor of breast cancer resistance protein and P-glycoprotein 
(Kruijtzer et al., 2002). Apparent oral bioavailability increased from 40% to 97% when 
inhibitor was administered with topotecan. As a reference intravenously adminstration to a 
separate group of subjects was used. 
The rate and extent of oral absorption
The rate and extent of oral drug absorption both determine the access of the drug to its site 
of action (Code of Federal Regulations, 2003). Drug absorption is characterised by 
pharmacokinetic parameters such as the area under the curve of drug concentration in 
plasma (AUC), maximum drug concentration in plasma (Cmax), the time for maximum 
concentration (tmax), and the mean residence time (MRT). The absolute bioavailability for 
the oral dosage form of a drug is the ratio between the AUC values for oral versus 
intravenous administration of an identical drug dose. Relative bioavailability is the ratio of 
different formulations, e.g., immediate-release versus controlled-release tablet. Oral drug 
absorption can be described by an apparent absorption rate constant (Ka). It can be 
calculated based on MRT values after administration of an oral solution (os) and i.v. 
injection (i.v.) using the following equation (Ritcshel and Kearns, 1999): 
(1)
..
1
vios
a MRTMRT
K
−
=
Drug bioavailability is one of the most critical pharmacokinetic factors when new oral 
drugs are developed (Abrahamsson and Lennernäs, 2004). Pharmacologically potent 
compounds may be inactive in vivo if the drug does not reach the target cells at adequate 
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concentrations. Poor bioavailability may be due to low solubility and dissolution of the 
drug, degradation in the gastrointestinal tract, low permeability across the gut wall, efflux 
to the gut lumen or extensive first-pass metabolism.  
High variability in drug absorption
Many drugs have acceptable concentration - time profiles and adequate bioavailability 
without formulation modifications, but have high inter- and/or intra-individual variability 
in drug concentrations. This can be due to variability in drug transit, distribution, 
dissolution, metabolism or permeability in the gastrointestinal tract, or differences in 
systemic kinetics i.e. distribution and elimination. For example, solubility and dissolution 
of acidic drugs is dependent on pH. Solubility is low and dissolution slow in the stomach, 
whereas high solubility and rapid dissolution may be achieved in the more alkaline 
conditions in the intestine. The main absorption site for drugs and nutrients is the small 
intestine, where the absorptive area is large (120 m2) compared to stomach (0.11 m2) 
(Avdeef, 2001). Gastric emptying of solid particles is a random, highly variable process. 
Gastric residence times of pellets with a size of 25 µm-14 mm may vary from 32 to 420 
minutes (Hunter et al., 1982; Jonsson et al., 1983). As a result of slow dissolution in the 
stomach, variable gastric emptying rates and rapid dissolution in the intestine, for an 
acidic drug the available concentration at the site of drug absorption may be highly 
variable. The Cmax of rapidly absorbed and/or eliminated drugs is especially sensitive to 
differences in the absorption phase (Kaus et al., 1999). To reduce high intra- and inter-
individual variability in drug absorption, the drug should dissolve rapidly in the stomach 
or in the duodenum. In that case, a high concentration of dissolved drug is available at the 
absorption site in the small intestine. To study the interplay of many time-dependent 
variables in drug absorption, the pharmacokinetic simulation model may be a useful tool. 
2.2 The gastrointestinal solubility and dissolution of drugs 
Drug solubility and dissolution in the gastrointestinal tract are dependent on physiological 
factors such as composition, volume, and hydrodynamics of the contents in the gut lumen 
(Dressman et al., 1998). Stomach, intestine and colon have different values for pH, fluid 
volumes, contents, hydrodynamics, and residence times. The stomach is acidic in the 
fasting state (pH 1.4-2.1) but its pH is elevated in the fed state (pH 3-7) (Dressman et al., 
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1990; Dressman et al., 1998). In the small intestine, the pH varies from 4.4 to 8.0 in the 
fasting and the fed states (Gray and Dressman, 1996). Bile salts are mainly secreted into 
the upper parts of the small intestine (Dressman et al., 1998). Bile salts and lecithin may 
lead to improved solubility and dissolution of low solubility drugs by forming mixed 
micelles in the fasting state. The volume of fluids in the fasting stomach is as little as 20-
50 ml (Wilson and Washington, 1989; Dressman et al., 1998; Schiller et al., 2005) and in 
the jejunum and ileum it is 120-350 ml (Dillard et al., 1965). Mixing in the stomach and 
intestine is more vigorous in the fed than fasting state. In the fasting stomach there are 
long periods of little or no motor activity. About every two hours “house-keeping” waves 
empty the stomach. Gastric emptying is a highly variable process both in the fasting and 
fed states. Residence times of solid drug particles in the stomach can vary from a few 
minutes to half a day (Dressman et al, 1998). In the fed state, the composition of meals 
consumed and the size of the solid drug particles have an effect on the residence time. 
Nutrient fluids empty by a regular contraction pattern with a regular frequency and 
amplitude. Solid particles with a size range of 1-2 mm may be emptied with nutrient 
fluids. Residence time in the intestine is 3.3 hours and it does not depend on nutrient status 
(Davis et al., 1986; Yu et al., 1996).  
High solubility drugs in rapidly dissolving immediate release formulations dissolve under 
variable conditions and active ingredients are mainly absorbed from the upper intestine. In 
the case of poorly soluble, poorly permeable drugs or controlled release formulations, the 
absorption may be slow, taking place over long segments of small intestine and colon. 
These drugs and products are sensitive to environmental factors such as physiological 
variables in the gastrointestinal tract (Dokoumetzidis and Macheras, 2006). For example, 
the release-controlling excipients in controlled-release formulations may be pH sensitive, 
as well as drug solubility. Thus gastrointestinal tract variables together with drug and 
formulation properties should be taken into account when an in vitro dissolution method is 
developed. Hydrodynamics and the complex composition of gastrointestinal fluids are the 
most challenging factors to be simulated in in vitro dissolution tests (Dressman et al., 
1998; Dokoumetzidis and Macheras, 2006). In vitro solubility and dissolution of low 
solubility drugs in aqueous buffers can underestimate the in vivo solubility and dissolution 
(Dressman, 2007). Thus the selection of medium for low solubility drugs is challenging.  
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2.3 Controlled-release formulations 
With rapidly eliminating drugs it may be difficult to achieve and maintain therapeutic drug 
concentrations. The average drug concentration in plasma at steady-state is dependent on 
the dosing frequency and dose size according to equation 2:  
(2)
τ*
*
CL
DoseFCss =
where Css is the average steady-state drug concentration in plasma, F is the bioavailability, 
CL (l/h) is the clearance rate, and  (h) is the dosing interval (Rowland and Tozer, 1995). 
To reduce dosing frequency, controlled-release formulations may be needed. There are 
several formulation techniques available to produce controlled-release formulations, e.g. 
excipient components may dissolve slowly in the gastrointestinal fluids or an undissolved 
matrix may release the drug slowly.  
The absorption window can be a critical factor when controlled-release formulations are 
developed (Davis, 2005). Some drugs which have an active transport mechanism or favour 
the paracellular absorption route have poor absorption from the colon (Lennernäs and 
Abrahamsson, 2004; Thombre, 2005). The extent of absorption in small intestine and 
colon is dependent on the BCS class of drug (Ungell et al., 1998). The in vitro Ussing 
chamber method was used to study drug absorption from rat intestinal and colonic tissues. 
Class I and II drugs were well absorbed from colon if the transport mechanism was 
passive diffusion, but Class III and IV drugs have significantly lower absorption from 
colon than from small intestine.  
2.4 The Biopharmaceutical Classification System 
2.4.1 Classifying drugs in BCS 
In 1995, Amidon and coworkers introduced the biopharmaceutical classification system 
for orally administered drugs (Amidon et al., 1995). Solubility, dissolution and 
permeability are the main factors that affect the rate and extent of oral absorption. Based 
on these properties, drugs are placed into four classes (Fig. 2). BCS class I drugs have 
high solubility and permeability, class II have high permeability but low solubility, class 
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III have low permeability and high solubility and for class IV drugs both permeability and 
solubility are low. Drug dissolution is classified as rapid if more than 85% of the dose is 
dissolved in 30 minutes.  
Detailed instructions for determining the BCS class of a drug are given in the regulatory 
guidelines (FDA guidance, 2000; EMEA, 2002). There are minor differences in 
methodology and application of BCS in the USA and Europe (Gupta et al., 2006). A drug 
substance has high solubility if the highest dose strength dissolves in 250 ml of aqueous 
buffer solution. According to the FDA guidance, solubility should be measured through a 
pH range of 1-7.5 and in the EMEA guidelines a pH range of 1-6.8 is required. Drug 
permeability is considered high if 90% or more of an orally administered drug is absorbed 
(FDA guidance, 2000). Linear and complete absorption indicates high permeability 
according to the EMEA guidelines (EMEA, 2002). Permeability can be determined based 
on in vivo mass balance studies or studies on absolute bioavailability (FDA guidance, 
2000). Intestinal permeability methods in vivo, in situ or in vitro can be used. Animal 
models and/or in vitro methods can be used for passively transported drugs. Instructions in 
the EMEA guidelines are more non-specific than those in the FDA guidance. Therefore, 
the EMEA guidance is currently under revision to generate more precise definitions and 
instructions for BCS biowaivers (EMEA, 2007).  
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Figure 2 Biopharmaceutical classification of drugs.  
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2.4.2 Applications of BCS  
BCS classification can be utilised in drug candidate selection at an early phase in drug 
development, during formulation development, and in regulatory applications (Lennernäs 
and Abrahamsson, 2005). The BCS class of a drug indicates the rate-limiting step for oral 
absorption: gastric emptying, dissolution or intestinal permeability (Fig. 3) (Amidon et al., 
1995). In the early development phase, the permeability and solubility boundaries can be 
set as selection criteria for new drug candidates (Abrahamsson and Lennernäs, 2004). In 
vitro methods are utilised to measure solubility and permeability. Solubility is typically 
measured by the shake-flask method and permeability by Caco-2 cells.  
BCS I BCS IIIBCS II and depot BCS IV
Rate-
limiting
step
Regulatory
strategy
Gastric
emptying
PermeabilityDissolution and/or 
solubility
Solubility and/or
permeability
BCS biowaiver IVIVC biowaiver BE studies BE studies
Development
strategy
Conventional IR
Many drug and/or
formulation
variables to be 
studied
Conventional IR or
prodrug
Many drug and/or
formulation
variables to be
studied
Figure 3 Application of the BCS in formulation development and appropriate regulatory strategies.  
BCS I drugs
Gastric emptying of the dissolved drug is the rate-limiting step for oral absorption of class 
I drugs with rapid dissolution (Fig. 3). Class I drugs have favourable absorption 
properties, leading to rapid and complete absorption. Drug absorption can be mediated 
either by passive transcellular diffusion or by active transport. Even simple, conventional 
immediate-release formulation assures rapid and complete absorption for this class of 
drugs. Therefore, formulation development is fast and cheap unless other issues, such as 
stability or production problems, exist. IVIVCs cannot be found for immediate-release 
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formulations of class I drugs if dissolution is faster than gastric emptying. Thus, the 
dissolution method can be a simple and cheap quality control tool. However, if a BCS 
biowaiver is utilised in a regulatory application, dissolution should be tested in three 
different media representing the pH range of the gastrointestinal tract. 
BCS II drugs
Dissolution controls absorption of class II drugs and a point-to-point relationship, i.e., 
level A IVIVC, can be found between in vitro dissolution and in vivo dissolution or 
absorption (Fig. 3). Like BCS I drugs, class II drugs have high permeability, and transport 
may be active or occur by passive transcellular diffusion. If absorption is limited by 
solubility or dissolution, it may be incomplete. Formulation development may be more 
challenging than for BCS I drugs if special tehniques and skills are utilised to enhance 
drug solubility or dissolution. For example, nanoparticles, microemulsion, cyclodextrins 
or lipid formulations can be used (Abrahamsson and Lennernäs, 2004; Lennernäs and 
Abrahamsson, 2005). In vitro dissolution method development also requires more time 
and a high level of knowledge if in vitro conditions are to mimic drug release and 
dissolution in vivo. Several pH values, agitation speeds, and different apparatuses should 
be tested. An appropriate method should discriminate critical formulation or 
manufacturing variables of the product affecting drug dissolution in vivo. If successful, a 
level A IVIVC may be proven and in vitro dissolution tests can be used as surrogates for 
in vivo bioavailability and bioequivalency studies.  
BCS III drugs
Class III drugs have permeability limited absorption (Fig. 3). Incomplete absorption due to 
limited permeability can rarely be solved by formulation factors, because specific and 
non-toxic permeability enhancers are difficult to develop (Lennernäs and Abrahamsson, 
2005). Instead, bioavailability may be increased by prodrug derivatization of the parent 
compound, improving drug distribution to the target tissue (Steffansen et al., 2004). The 
prodrug can be more lipophilic than the parent drug, faciliating trancellular passive 
diffusion or, alternatively, the prodrug can be designed to be a substrate for a transporter. 
The lipophilicity of the angiotensin-converting enzyme (ACE) inhibitors has been 
increased by using the ethyl ester, as for example was done with the prodrug of enalapril 
(Abrams et al., 1984; Todd and Heel, 1986; Beaumont et al., 2003). Bioavailability of the 
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parent compound is 3%, which improves to 36-44% for the ester prodrug. Valaciclovir, a 
prodrug of acyclovir, utilises an oligopeptide transporter and has 5 times better 
bioavailability than acyclovir (Han et al., 1998). 
In many cases, permeability is high enough to achieve therapeutic drug concentrations in 
plasma. Then conventional immediate-release formulation is a good choice. For example, 
the BCS III drugs ranitidine and cimetidine in immediate-release tablets have 
bioavailabilities of 50-60% (Bogues et al., 1980; Garg et al., 1981; Jantratid et al., 2006). 
In many cases, the prodrug approach is not needed if therapeutic drug concentrations are 
achieved with the parent drug and with simple and cheap conventional formulations.  
An IVIVC can not be found for BCS III drugs when permeability is the rate-limiting step 
for absorption. The role of the dissolution method is to act as a quality control tool to 
ensure batch-to-batch consistency. Dissolution method development is thus easier for such 
class III drugs than for class II drugs or controlled-release products.  
BCS IV drugs
Class IV drugs have low solubility and permeability. The rate-limiting step in drug 
absorption can be solubility, dissolution or permeability (Fig. 3). The fraction of absorbed 
drug dose may be low and highly variable because class IV drugs have problems in 
solubility and permeability. Formulation and dissolution methods may be similar to those 
for class II drugs if dissolution is the rate-limiting factor. For permeability-limited 
absorption, class IV drugs may be developed like class III drugs. Some class IV drugs may 
be unsuitable for oral administration if the fraction absorbed is too low and oral absorption 
is highly variable. However, the tolerated level of variability depends on the indication 
and therapeutic index of the drug.  
2.4.3 BCS biowaivers 
Bioequivalence studies may be replaced by BCS or IVIVC biowaivers (Fig. 3). For a 
biowaiver, the in vitro dissolution study may be used as a surrogate for in vivo
bioequivalence studies. The first regulatory guidance utilising the BCS was published in 
1995, when the FDA published a guidance for scale-up and post-approval changes 
(SUPAC) of drug products (FDA guidance, 1995). Requirements were based on the BCS 
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class of the drug in question and the significance of the change. SUPACs are divided in 
three levels: level 1 changes are unlikely to have any detectable impact on formulation 
quality and performance; level 2 changes could have a significant impact; and at level 3 
the changes are likely to have impact on bioavailability. Level 2 changes can be applied 
for based on presentation of data for rapid dissolution for BCS I drug products, and 
presentation of dissolution profile comparisons for BCS class II or III drugs. Level 3 
changes have to be justified by in vivo studies if a level A IVIVC is not found.  
BCS biowaiver guidelines were introduced in 2000 by the FDA and in 2002 by EMEA 
(FDA guidance, 2000; EMEA, 2002). In vivo bioequivalency studies may be replaced by 
in vitro studies for BCS I drugs if test and reference drug products have similar dissolution 
profiles (Fig 2.). In the USA, drug products should also have rapid dissolution, i.e. > 85% 
should dissolve in 30 minutes at three different pH values (range 1-6.8) (FDA guidance, 
2000). To be a biowaiver candidate, the application should include scientific justification, 
e.g. that the drug does not have a narrow therapeutic index and that all excipients are well-
know (FDA guidance, 2000; EMEA, 2002). Importantly, the excipients should not have 
interactions with the pharmacokinetics of the drug component. Atypically large amounts 
of known excipients or new excipients in the drug formulation require additional 
information in the regulatory application.  
Currently, BCS I drugs are defined as biowaiver candidates because the rate limiting step 
for absorption is gastric emptying of the dissolved drug. Minor differences in the 
dissolution rates therefore have negligible effects on Cmax and AUC. Conventional 
immediate-release dosage forms should behave more like oral solutions. However, the 
rate-limiting step for absorption can be a complex combination of several factors, i.e., 
gastric emptying, solubility, and dissolution can all contribute to the absorption rate of the 
drug. Despite its merits, the BCS classification is an oversimplification of the dynamic 
process of oral drug absorption. 
2.4.4 BCS biowaiver extensions 
During the time period spanning 2000-2007, regulatory agencies have received fewer BCS 
biowaiver applications than expected. This is the case especially for new generic drug 
products (Polli et al., 2004; Barends, 2005; Gupta et al., 2006, EMEA, 2007). There are a 
few published revisions to methodologies for classifying drugs in the BCS, and extension 
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of biowaivers to acidic class II and class III drugs has been suggested. Hopefully these 
will lead to BCS guideline revisions and increase BCS biowaiver applications.  
Methodology revisions 
It has been suggested that the solubility boundary for biowaiver candidates should be 
narrowed from pH 1-7.5 to 1-6.8 and the fraction of the dose absorbed should be reduced 
from 90% to 85% (Yu et al., 2002; Polli et al., 2004). Currently, a drug product is 
considered rapidly dissolving if more than 85% dissolves in 30 minutes. A new criterion 
of 60 minutes for the dissolving time has been suggested (Polli et al., 2004). For acidic 
drugs, solubility tests in conditions mimicking small intestinal pH may be more 
appropriate than tests performed at pH 7.5 (Yazdanian et al., 2004). To classify drug 
solubility, the solubility is measured in aqueous buffer using a volume of 250 ml. It has 
been suggested that the volume should be increased from 250 ml to 500 ml and that 
surfactants may be added to the medium (Polli et al., 2004). However, these revisions need 
experimental verification before they can used.  
BCS II drugs 
BCS II drugs have not been accepted as biowaiver candidates by the regulatory agencies, 
but acidic BCS II drugs have been suggested as possible candidates for biowaivers in 
scientific publications (Rinaki et al., 2004; Yazdanian et al., 2004). Those publications 
criticise the current biowaiver guidelines, which are based on equilibrium solubility and 
dissolution tests, and in which the dynamic nature of drug absorption is not taken into 
account. Acidic BCS II drugs have low solubility only in the stomach, while solubility in 
the small intestine is high and the fraction of the dose absorbed can be > 0.9. The extent of 
oral drug absorption (i.e. AUC) may not be sensitive to minor dissolution rate differences 
under the alkaline conditions in the small intestine. In contrast, the rate of oral absorption 
(i.e. Cmax) may be sensitive to differences in the dissolution rates, as was pointed out in 
simulation studies (Kaus et al., 1999). Solubility and dissolution of acidic BCS II drugs 
are site dependent, i.e., solubility is low in the acidic stomach and high in the alkaline 
small intestine. As discussed previously, gastric emptying of solid drugs is a highly 
variable process, since house-keeping waves occur every 1.3-2 hours (Wilson and 
Washington, 1989). Thus, drug concentrations at the absorption site may vary and minor 
dissolution rate differences may cause fluctuations in Cmax values.  
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BCS III drugs 
For BCS III drugs, biowaivers can not be utilised in regulatory applications in the USA 
and Europe, but in a report recently published by the WHO, BCS III drugs were accepted 
as biowaiver candidates (WHO, 2006). There are many scientific papers published where 
class III drugs are recommended as a biowaiver candidates (Blume and Schug, 1999; Yu 
et al. 2002; Cheng et al. 2004; Vogelpoel et al. 2004; Polli et al., 2004). For this BCS 
class, the permeability rate controls absorption and the bioavailability is more dependent 
on the drug (permeability) than on the formulation (dissolution). The test and reference 
products will be bioequivalent if absorption is permeability rate limited. Class III drugs 
may be even better biowaiver candidates than class I drugs, if the effects of excipients on 
gastrointestinal transit time and permeability can be excluded (Blume and Schug, 1999). 
BCS III drugs which are substrates of efflux proteins and/or have extensive metabolism in 
the intestine should not be accepted as biowaiver candidates. These saturable mechanisms 
are dependent on drug concentration and thus in some cases even minor differences in the 
concentration can lead to changes in the rate and/or extent of absorption.  
2.5 In vitro-in vivo correlation 
2.5.1 Level A, B and C IVIVC 
Drug dissolution is the rate-limiting step in absorption for BCS II drugs and controlled 
release formulations (Fig 3). Therefore, in vitro dissolution of the drug correlates with its 
in vivo absorption. To predict in vivo input rate, the dissolution method should 
discriminate between the variables of drug substance, product and/or manufacturing 
method that affect the rate and extent of drug release and dissolution. In the most 
successful case, in vitro dissolution conditions that mimic in vivo dissolution may be 
found.  
For reasons of clarity, three levels - A, B and C - have been defined for IVIVC (FDA 
guidance, 1997). Level A IVIVC is the highest level and it has the most extensive 
applications. It represents a point-to-point relationship between in vitro dissolution and in 
vivo input rate. Only in the case of level A IVIVC can in vitro dissolution be used as a 
surrogate for in vivo bioequivalence studies, i.e., the level A IVIVC model and dissolution 
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method can be used in biowaivers. Level B and C IVIVC models have less predictive 
power a than level A IVIVC model, because Cmax, Tmax or MRT values can be the same 
for different formulations. In level B IVIVC, parameters are based on statistical moment 
analysis. Typically, MRT or mean dissolution time in vivo (MDTin vivo) is compared to the 
mean dissolution time in vitro (MDTin vitro). Level C IVIVC represents single-point 
correlation between one dissolution time point and one pharmacokinetic parameter. For 
example, the time for 80% drug release can be correlated with Cmax.  
2.5.2 Development of a level A IVIVC model 
To develop and validate a level A IVIVC model, two or three different formulations 
should be studied in vitro and in vivo (FDA guidance, 1997). Typically, the qualitative 
composition of drug products is the same, but the release-controlling variable(s), e.g., the 
amount of excipient, or a property of the drug substance such as particle size, is varied. To 
develop a discriminative in vitro dissolution method, several method variables together 
with formulation variables are studied, e.g., different pH values, dissolution apparatuses 
and agitation speeds.  
Development of a level A IVIVC model includes several steps. In the first step, the in vivo
input profile of the drug from different formulations is calculated from drug 
concentrations in plasma (Fig. 4). To separate drug input from drug distribution and 
elimination, model-dependent approaches, such as Wagner-Nelson and Loo-Riegelman, or 
model independent procedures, based on numerical deconvolution, may be utilised 
(Wagner and Nelson, 1964; Loo and Riegelman, 1968; Cutler, 1978; Veng-Pedersen, 
1992). The Wagner-Nelson protocol for a one-compartment model is the simplest method, 
because an i.v., oral solution or immediate-release formulation is not needed as a 
reference. Loo-Riegelman two-compartment and numerical deconvolution methods 
require administration of a reference formulation. In step 1, the parameters that describe 
drug input rate, drug distribution and/or elimination are determined. In the model 
dependent approaches, the distribution and elimination rate constants describe 
pharmacokinetics after absorption. In the numerical deconvolution approach, the drug unit 
impulse response function describes distribution and elimination phases, respectively.  
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Figure 4 The main steps in the development of a level A IVIVC model.  
In step 2, the relationship between in vitro dissolution and the in vivo drug input profile is 
determined (Fig. 4). Either a linear or nonlinear relationship may be found. In some cases, 
time-scaling of in vitro data must be used, because in vitro dissolution and in vivo input 
may follow the same kinetics but still have different time-scales (Brockmeier et al., 1983; 
FDA guidance, 1997). The time-scaling factor should be the same for all formulations if 
an IVIVC at level A is sought.  
In step 3, plasma drug concentration profiles are predicted and compared to the observed 
time courses for different formulations (Fig. 4). To generate predicted time courses, the 
drug input profile is predicted based on in vitro dissolution data and the in vitro-in vivo
relationship generated in step 2. In the convolution process, the predicted drug input and 
parameters describing drug distribution and/or elimination phases are combined in order to 
get predicted time courses. This procedure, which includes steps 1-3, is called two-stage 
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deconvolution. Alternatively, a drug input profile based on in vitro dissolution data can be 
solved together with parameters describing systemic pharmacokinetics, i.e. distribution 
and elimination. This approach is called direct convolution. 
Internal and external predictability of a level A IVIVC model
The predictability of a level A IVIVC model is tested by calculating percent prediction 
error (%PE): 
(3) 100)(% ×






−
=
observed
predictedobservedPE
where the observed and predicted values of Cmax and AUC are used. A level A IVIVC 
model has acceptable predictability if the average percent prediction errors for the 
formulation series are less than 10% (FDA guidance, 1997; EMEA, 2000). In addition, the 
percent prediction error for each formulation should not exceed 15%. Validity of IVIVC 
models can be tested internally with data used to define the IVIVC, or externally with data 
that was not used for model development. External predictability has tighter limits for 
percent prediction error (10%) and it is recommended especially for narrow therapeutic 
index drugs.  
2.5.3 Applications of IVIVC models 
The main objective of developing and validating IVIVC models is to establish conditions 
for dissolution tests which can be used as surrogates for relative bioavailability or 
bioequivalence studies. Several bioavailability and bioequivalence studies are conducted 
during the development process of a new drug product. The manufacturing scale of the 
drug product is increased from laboratory scale via a pivotal scale to the final production 
scale, and typically the regulatory application for a new drug includes several strengths 
(Lennernäs and Abrahamsson, 2005). BCS II and controlled-release drugs also need 
formulation optimisation studies in order to achieve target drug concentrations in plasma. 
Another application of IVIVC models is for drug products already on the market which 
need some alteration, for example because of changes in manufacturing site, equipment, 
process or formulation. In general, if an IVIVC biowaiver can not be utilised, several 
formulations and strengths need to be studied in vivo leading to higher costs and longer 
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development times. 
Level B and C IVIVC models do not have extensive possibilities for use in biowaiver 
applications, because they do not represent point-to-point relationships between in vitro
and in vivo parameters. Different types of formulations can have the same AUC, Cmax or 
Tmax values, even if the shapes of the concentration profiles are different. Thus, level B or 
C IVIVC models cannot be used to replace relative bioavailability or bioequivalence 
studies.  
The possibilities for successful development and use of a level A IVIVC model depend on 
the quality of the in vivo data i.e. how many subjects are involved in the study, whether the 
study involves administration of reference drug, and how many different formulations are 
studied. The most important thing is to use a logical series of formulations in the in vivo
study in order to validate the IVIVC model.  
Averaged IVIVC models
There are many published studies where an averaged level A IVIVC model is developed 
for one immediate-release formulation of BCS II drug (Nicolaides et al., 2001), for one 
modified-release formulation (Mahayani et al., 2000; Modi et al., 2000; Dalton et al., 
2001) or for a logical series of modified-release formulations (Eddington et al., 1998; 
Sirisuth and Eddington, 2000; Veng-Pedersen et al., 2000; Sirisuth et al., 2002a; Sirisuth 
and Eddington, 2002b). Averaged IVIVC models for one or two formulation(s) have 
limited possibilities for use in biowaver applications because only minor changes to the 
manufacturing process or formulation may be applied for based on an IVIVC biowaiver 
(FDA guidance, 1997). Averaged IVIVC models for logical series of formulations have 
more extensive possibilities for use in biowaiver applications because interpolation is 
possible within the formulation series. Formulations utilised in IVIVC model development 
have the same qualitative composition and the same release- and dissolution-controlling 
factors, but different dissolution rates. Then, approval of even major changes, e.g. changes 
to release-controlling excipients, may be applied for. However, the change should be 
within the range of release-controlling excipients for the established correlation.  
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Stochastic IVIVC models
The information from the original in vitro and especially in vivo data may be lost when an 
IVIVC model is constructed using the averaged approach. In many cases inter- and intra-
subject variability in pharmacokinetics is much greater than the variability between 
formulations (Mauger and Chinchilli, 1997). Thus the averaged level A IVIVC model may 
be misleading or model development may fail. A stochastic model, representing data 
variability as well as uncertainty related to both the subjects and the ability of the IVIVC 
model to describe observed data, may be integrated into a level A IVIVC model. Most of 
the stochastic IVIVC models are developed for one formulation, not for a formulation 
series (Bigorra et al., 1997; Mauger and Chinchilli, 1997; Verotta, 1997; Dunne et al., 
1999; O’Hara et al., 2001; Pitsiu et al., 2001; Qiu et al., 2003). In these studies mixed 
effect approaches have been combined with IVIVC models to describe variability related 
to the in vivo data.  In this type of level A IVIVC model, all subjects are modelled 
simultaneously and, depending on the in vivo study design, intra- and/or inter-individual 
variability related to the subjects can be taken into account in the predictions. In most 
published examples, the deconvolution step is involved i.e. comparison of in vitro
dissolution and in vivo input curves (Bigorra et al., 1997; Verotta, 1997; Dunne et al., 
1999; Qiu et al., 2003). A convolution approach together with mixed effect modelling has 
been presented in one publication, where concentration profiles of one formulation were 
predicted for each subject (Pitsiu et al., 2001). There is one published example of 
development of a mixed effects IVIVC model for a formulation series (Mauger and 
Chinchilli, 1997). In that study, the model construction and validation were not presented 
in sufficient detail. Thus there is need for transparent stochastic IVIVC models for 
formulation series, which can utilised both during drug development and in the post-
approval period. Level A IVIVC model can be validated, when it is constructed to the 
formulation series. The Bayesian approach enable the use of subject-specific in vivo data 
and probably better predictability is achieved than with corresponding averaged level A 
IVIVC models.  
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2.6 Regulatory applications of biowaivers  
In many cases in vivo bioequivalence studies can be replaced by in vitro dissolution 
studies in regulatory applications. The application can be based on BCS or IVIVC 
biowaivers or simply on a dissolution profile comparison. BCS biowaivers have the most 
extensive possibilities for use in drug approval applications, because they can be used in 
applications for approval even of new generic drug without in vivo bioequivalence studies. 
A BCS biowaiver is acceptable for BCS class I drugs formulated as rapidly dissolving 
immediate-release products (FDA guidance, 2000; EMEA, 2002). In that case, the 
application may be based on in vitro dissolution and permeability data together with 
scientific justification of linear pharmacokinetics, a proof that the drug does not have a 
narrow thepapeutic index and that the excipients do not have pharmacokinetic interactions 
with the drug. Both BCS and IVIVC biowaivers can be utilised for changes in drug 
product composition, manufacturing site or production method. An IVIVC biowaiver can 
be used for BCS II drugs in immediate-release dosage forms and for controlled-release 
formulations.   
Approval of new, lower strengths or some minor changes to the drug product can be 
applied for based on the dissolution profile comparison without IVIVC or BCS 
biowaivers. Then, to guarantee bioequivalency, the new dose strength or new formulation 
should have a similar dissolution profile to that of the drug formulation already on the 
market. IVIVC and BCS biowaivers can be utilised even for major changes which are 
known to have some effect on drug absorption. However, the classification of changes as 
minor or major is different in the USA and Europe, and there are even differences in such 
classification between national European agencies. 
2.7 Quantitative absorption models 
In the BCS, the dynamic nature of drug solubility, dissolution and permeability is not 
taken into account. The BCS can be used to estimate oral drug absorption, but a 
quantitative approach is more accurate and informative. Maximum absorbable dose, 
fraction of dose absorbed or rate-limiting step for drug absorption can be estimated when 
in silico, in vitro or in vivo parameters such as solubility, dissolution, and permeability are 
gathered together. In addition, relevant physiological factors, like small intestinal transit 
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time, liquid volumes, and pH values in the gastrointestinal tract, can be taken into account 
in a quantitative absorption model.  
2.7.1 Prediction of fraction of dose absorbed and maximum absorbable dose 
Maximum absorbable dose (MAD)
MAD is a useful parameter for new drug candidates. In addition to solubility and 
permeability, transit time in small intestine and water volume are used to calculate MAD 
(Curatalo, 1998) using equation 4: 
(4) TVKSMAD a ×××=
where S is drug solubility, Ka is the absorption rate constant, V is the intake water volume 
(250 ml) and T is the transit time in small intestine (199 min). MAD can also be calculated 
using the following equation (Sun et al., 2004): 
(5) TASPMAD effeff ×××=
where Peff is drug permeability in human intestine and Aeff is the effective absorption 
surface area. Peff can be replaced with in vitro Caco2 permeability data using the following 
equation (Sun et al., 2004):  
(6) )3036.0log6532.0( 2,10 −= CacoeffPeffP
Mass balance approach
The mass balance approach can be used to predict fraction of dose absorbed (Fabs) and to 
estimate critical factors affecting the extent of drug absorption (Amidon et al., 1995). 
However, plasma concentration profiles cannot be predicted with this kind of steady-state 
model. Three dimensionless-parameters, i.e. dose number (Do), dissolution number (Dn) 
and absorption number (An), are utilised in predictions (Amidon et al., 1995; Löbenberg 
and Amidon, 2000). Dose number is equal to the Q value (Rinaki et al., 2003a) according 
to equation 7: 
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(7)
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where S is solubility and V is liquid volume in stomach or intestine (250 ml). High 
solubility drugs have Q<1 and low solubility drugs have Q>1. Absorption number is  
(8)
abs
res
T
TAn =
where Tres is mean small intestinal transit time and Tabs is mean absorption time, which 
can also defined as follows: 
(9)
eff
abs P
RT =
where R is radius of the tube (small intestine) and Peff is effective permeability. For drugs 
with complete absorption, the value of An is more than one, and incomplete absorption 
gives a value of An that is less than 1.  
Dissolution numbers is  
(10)
diss
res
T
TDn =
where Tdiss is the mean dissolution time, which can also defined as follows: 
(11)
DS
rTdiss 3
2
0 ρ
=
where ro is the initial particle radius,  is density of the particle and D is the diffusion 
coefficient. To obtain parameters for calculating mean dissolution time, theoretical 
assumptions should made. However, from in vitro dissolution data, mean dissolution time 
can be determined e.g. with a the Weibull function. Drugs with complete dissolution have 
a Dn value greater than one, and incomplete dissolution lead to a Dn value of less than 1.  
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Quantitative BCS
Fabs can be predicted semi-quantitatively with a quantitative BCS model (Rinaki et al., 
2003b). The method is based on a tube model, where drug particles move down the tube, 
dissolve in the intestinal fluids and permeate through the intestinal wall. Mean transit time 
in the intestine (MITT), mean dissolution time (MDT), mean absorption time (MAT) and 
mean effective time (MET=MAT+MDT) describe these processes. Drugs can be 
categorised, for example, as fully absorbed (Fabs>0.95) when MET<< MITT, and as 
having dissolution limited absorption when MET>>MAT and therefore MDT>>MAT.  
2.7.2 A dynamic model to predict drug concentration profile 
The compartmental absorption and transit model (CAT) is a dynamic model by which 
both Fabs and drug plasma concentration profiles can be predicted (Yu et al., 1996; 
Agoram et al., 2001). In the CAT model, drug absorption and gastrointestinal transit 
processes are described with nine compartments (Yu et al., 1996; Yu and Amidon; 
1999b). Stomach and colon are described as one compartment each and the small intestine 
as seven compartments. In the CAT model, gastrointestinal tract physiology (gastric 
emptying, small intestinal transit and distribution), physico-chemical (permeability, 
solubility), and pharmaceutical (release and dissolution) factors can be easily taken into 
account. Pharmacokinetic parameters describing drug distribution and/or elimination 
phases can be integrated into the CAT model in order to predict the concentration-time 
profile (Agoram et al., 2001). Both linear non-saturable and non-linear saturable processes 
can be taken into account and simulated with the CAT model. However, the biggest 
challenge is to scale the in vitro data describing drug dissolution, transport or metabolism 
to correspond to in vivo processes in humans.  
2.7.3 Comparison of different methods to predict the rate-limiting step of 
absorption 
BCS classes I and II include diverse drugs for which the absorption may depend on gastric 
emptying, solubility and/or dissolution. Quantitative kinetic models may be useful for 
identification of the rate limiting steps. Then, variables related to the drug substance, drug 
product and gastrointestinal tract physiology can be taken into account simultaneously, 
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and the most critical factors in drug absorption may be determined. 
The rate-limiting step for absorption of digoxin, a BCS I drug, has been estimated using 
several quantitative absorption models. Based on the BCS classification, the rate-limiting 
step for absorption of digoxin from immediate-release formulations should be gastric 
emptying. Absorption of digoxin was studied using the mass balance approach 
(Löbenberg and Amidon, 2000). Dose number, absorption number and dissolution number 
were plotted to find critical factors determining the extent of drug absorption. The extent 
of absorption of a high permeability drug with a relative low dose number, like digoxin 
(Do=0.08), is sensitive to the to dissolution rate differences. Thus, absorption of digoxin 
can be increased with faster dissolving products like micronized drug subtance. 
Quantitative BCS was utilised for digoxin (Rinaki et al., 2003b). Mean dissolution time 
was longer than the mean absorption time, indicating dissolution-dependent drug 
absorption. An integrated drug absorption model (that resembles the CAT model) was 
used to predict particle size effects on digoxin absorption (Yu, 1999a). The model showed 
that absorption was dependent on particle size, and it was able to predict the empirical in 
vivo data. It can be concluded, based on all three quantitative absorption models, that the 
rate-limiting step for digoxin absorption is dissolution instead of gastric emptying (Yu, 
1999a; Löbenberg and Amidon, 2000; Rinaki et al., 2003b). This is in agreement with the 
empirical findings (Jounela et al., 1975). Relative bioavailabilities from immediate-release 
tablets with 0.25 mg of digoxin were 96, 78 and 37% for particle sizes of 7, 13 and 102 
µm, respectively. In this study, oral solution was used as the reference. Quantitative 
absorption models are needed for characterization of the rate-limiting step for absorption 
and to guide formulation and regulatory strategies for oral dosage forms.  
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3 Aims of the study 
The overall aim of the study was to generate and utilise pharmacokinetic and IVIVC 
models to facilitate formulation development and preparation of regulatory applications. 
The specific goals of the study are: 
1. To develop and select a predictive dissolution method for a level A IVIVC model of 
levosimendan modified-release capsules.  
2. To develop a level A IVIVC model using a Bayesian approach for a levosimendan 
modified-release formulation series by utilising subject-specific in vivo data. The 
final goal of the model was to obtain in vivo predictions as probability distributions.  
3. To evaluate ranitidine, a BCS III compound, as a potential biowaiver drug.  
4. To build a pharmacokinetic simulation model to evaluate the relative risks of 
bioinequivalence and to suggest candidates for biowaivers among BCS I-IV drugs. 
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4 Materials and methods  
4.1 IVIVC studies (I, II) 
4.1.1 Development of a biorelevant dissolution method for levosimendan (I) 
In vitro and in vivo data 
In the formulation series (F, G, H and I), the dissolution and absorption of levosimendan 
was slightly extended by formulation factors i.e. the amount of release controlling 
excipients increased from formulation F to I. The qualitative composition of the 
formulations was the same. The in vitro dissolution rate of levosimendan was studied 
using the basket method at pH 5.8 or 7.4. Levosimendan concentrations in the samples 
were analysed by UV spectrophotometer.  
Levosimendan absorption from the oral formulations was studied in nine healthy 
volunteers. Drug concentrations in plasma were determined by reversed-phase high 
performance liquid chromatography using UV detection (Karlsson et al., 1997).  
Data analysis
In order to select a biorelevant and discriminative dissolution method for the modified 
release formulations, in vitro dissolution and in vivo bioavailability data were analysed by 
several methods. To test in vivo relevance of different dissolution methods, level B and C 
IVIVC models were constructed for the formulation series, and a level A IVIVC model for 
one of the formulations. To test how dissolution methods discriminate between the 
formulations, the dissolution profiles were compared using similarity factors (f2) (Moore 
and Flanner, 1996). Pharmacokinetic parameters, Cmax, AUC, Tmax and MRT were 
calculated. The differences in pharmacokinetic parameters were determined with statistical 
analysis of variance (ANOVA). In all calculations, commercial software was utilised.  
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4.1.2 Development of a stochastic IVIVC model for levosimendan formulations (II) 
In vitro and in vivo data 
In the development of the stochastic level A IVIVC model, the Bayesian approach was 
combined with the pharmacokinetic one-compartment model. In vitro and in vivo data 
from publication I and two additional levosimendan absorption studies, as well as related 
dissolution data, were used in the model construction and predictability tests (II, Fig.1). In 
this study, formulation codes A, B, C and D were used for formulations F, G, H and I, 
respectively. 
One-compartment modelling
In vitro dissolution and in vivo absorption data were combined in a convolution model 
modified from a pharmacokinetic one-compartment model (Wagner and Nelson, 1964).  
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where Ka is the apparent absorption rate constant, F is bioavailability, Dpo is the per oral 
dose of levosimendan, Vc is the volume of the central compartment, k10 is the elimination 
rate constant, and tlag is the lag time of drug absorption. The one-compartment model was 
modified by replacing the Ka with a dissolution rate constant (Kd) and a time-scaling 
factor (a).  
The stochastic IVIVC model
In order to build the stochastic IVIVC model, subject-specific absorption data were used. 
A Bayesian approach was combined with the modified one-compartment model. The most 
important part of the stochastic IVIVC model is the likelihood function that defines the 
connection between the modified one-compartment model parameters (a, F/Vc, K10, tlag) 
and the experimental data (Gelman et al, 1995). The explanatory variable was Kd, the first 
order rate of in vitro dissolution. That parameter was measured at pH 5.8 using a rotation 
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speed of 100/min for each formulation. A log-normal noise model was used to explain the 
deviations of levosimendan concentrations in plasma from the compartment model. As a 
result of simulations, the marginal posterior distributions for modified one-compartment 
model parameters were obtained. By combining posterior distribution of model parameters 
with the dissolution data, we predicted the drug concentration profiles in plasma for each 
formulation. The concentration-time profiles were presented as maximum values of the 
posterior distribution (MAP) and as 95% probability intervals. The predicted parameters 
(AUC, Cmax) were presented as histograms and MAP. In all calculations, MATLAB 
(MathWorks Inc., USA) was utilised.  
4.2 Risk analysis studies of bioequivalence and biowaivers (III,IV)  
4.2.1 Evaluation of ranitidine as a biowaiver candidate (III)  
Relevant literature data was collected for ranitidine immediate-release dosage forms. The 
data included solubility and dissolution values, permeability, pharmacokinetic parameters, 
therapeutic use, and therapeutic window. Furthermore, data about excipient interactions 
and problems of bioavailability and/or bioequivalence was collected. The Caplus, Ipa and 
Medline databases were utilised. Solubility data from the literature did not cover the entire 
physiological pH range. Therefore, solubility determinations were carried out. Ranitidine 
suspensions were shaken in buffer solutions covering the relevant pH range and the 
concentrations of dissolved ranitidine were analysed by high performance liquid 
chromatography.  
Literature data was compared to the current BCS biowaiver requirements defined in the 
guidelines (FDA guidance, 2000; EMEA, 2002) and in scientific papers suggesting 
extensions to the current requirements. BCS classification of ranitidine was done based on 
experimental solubility determinations and in vitro Caco-2 studies published in the 
literature. Risks related to the bioequivalence of different immediate-release dosage forms 
were estimated based on dissolution properties and excipients used in immediate-release 
formulations on the market in Germany, the Netherlands and Finland. 
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4.2.2 Simulated risk analysis for bioequivalence and biowaivers (IV) 
Computer simulations were carried out to probe the sensitivity of Cmax and AUC to 
dissolution rate. In all cases, oral solution was compared to immediate release 
formulations and the relative changes in Cmax and AUC were simulated.  
The model structure
Gastric emptying, drug dissolution, transit in the intestine and absorption were all 
incorporated into the compartment absorption and transit model (CAT) (Fig. 5) (Yu et al., 
1996). The stomach was described as a single compartment and the intestine as seven 
compartments in series. In the simulations, the drug was allowed to dissolve both in the 
stomach and intestine, but absorption took place only in the intestine. Solid and dissolved 
drug were transferred from the stomach to the intestine. Thereafter, the transit and 
distribution of the undissolved and dissolved drug in the intestine were similar. After its 
first-order absorption, the drug was assumed to obey one-compartment kinetics with a 
first-order rate of elimination from plasma. The model was constructed using STELLA 
software (ISEE systems, Lebanon, USA).  
Solid
Solid
Solution
Solution Plasma
Kd
KaKd Kel
Stomach 
Intestine 1st
compartment
Intestine 2nd-7th
compartment
KgeGE
Kt1 Kt2
Intestine 2nd-7th
compartment
Figure 5 The structure of the CAT model and parameters used in the model: GE is gastric 
emptying for solid drugs, Kge is the gastric emptying rate constant for dissolved drug, Kd is the 
dissolution rate constant, Kt1 and Kt2 are transit rate constants for solid and dissolved drug 
respectively, Ka is the absorption rate constant and Kel is the elimination rate constant. The drug 
transits, dissolves and absorbs identically from all 7 compartments of the intestine.  
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Gastrointestinal parameters 
Literature data from imaging studies was analysed to obtain parameters describing the rate 
and kinetics of gastric emptying after administration of oral solution and solid 
formulations with single or multiple units (IV, Table 1). Oral solution empties from the 
stomach according to first-order kinetics, multiple unit formulations use zero-order 
kinetics, and single-unit formulations empty as a single rapid bolus. Fast, average and 
slow gastric emptying rates were calculated based on the literature data for multiple and 
single unit formulations.  
Rates of drug dissolution, absorption and elimination
The rate of drug dissolution in the model was set at either 2 h-1 or 4 h-1, and these 
hypothetical formulations were compared to the performance of drug solution. A 
dissolution rate constant of 4 h-1 means that more than 85% of the drug is dissolved in 30 
minutes, whereas at Kd = 2 h-1 more than 85% of the drug is dissolved in 60 minutes. 
In the simulations, the rates of drug absorption (Ka) had a wide range (0.1-8 h-1) that spans 
the scale of both high and low permeability drugs of the BCS (IV, Table 2). Absorption 
rate constants of 1.2-8 h-1 enable complete drug absorption (>90%). Low permeability 
drugs have absorption rate constants of 0.1-0.8 h-1 and they show incomplete absorption. 
The range of elimination rate constants was 0.014-0.9 h-1. There were 366 clinically used 
drugs in this range as of 1999 (Ritschel and Kearns, 1999).  
The parameter values that were used in the simulations overlapped all four BCS classes. In 
the simulations, the BCS II and IV drugs were assumed to be acids, i.e., they had low 
solubility in the stomach and high solubility in the intestine. 
Risk assessment of bioequivalence studies and potential for biowaivers 
The AUC and Cmax values were simulated and the ratios of these values for oral solid 
formulation over those for oral solution (oral solid formulations/oral solution) were 
calculated for each set of parameter combinations. Multiple and single unit dosage forms 
were studied using fast, average and slow gastric emptying rates in the fasting state. For 
bioequivalence and biowaiver criteria we suggest here a maximum of 10% difference in 
AUC and Cmax between the solid dosage forms and oral solution. 
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5 Results 
5.1 IVIVC for levosimendan modified-release capsules (I, II) 
5.1.1 Dissolution and absorption properties of different formulations (I, II) 
In vitro dissolution properties
Levosimendan dissolution was rapid at pH 7.4 from all formulations (F, G and H) when 
the speed of rotation was 100 rpm (Fig. 6). At a rotation speed of 50 rpm, the dissolution 
rate decreased. Formulation G had slower dissolution than formulation H. At pH 5.8, 
higher amounts of rate-controlling polymers caused slower dissolution rates (Fig. 7). The 
best discrimination was achieved at pH 5.8 and a rotation speed of 50 rpm. In this case the 
similarity factors (f2) were less than 50, indicating dissimilar dissolution profiles among 
all formulations. Formulations F, G, and H had similar dissolution profiles at pH 5.8 and a 
rotation speed of 100 rpm, but formulation I differed from all the others. 
In vivo absorption properties
The pharmacokinetic parameters Cmax, AUC, Tmax and MRT for formulations F through I 
are presented in Table I. An increased amount of alginic acid and 
hydroxypropylmethylcellulose decreased the rate of drug absorption from the 
formulations. There was a rank-order correlation between the amount of rate-controlling 
excipients and the values of MRT and Cmax. Differences in the Cmax values were 
statistically significant (p<0.05) between formulations F vs. H, F vs. I, and G vs. I. Based 
on Tmax and MRT values, drug absorption from formulation I was significantly slower 
than from all the others, whereas formulations F, G and H did not statistically significantly 
differ from each other.  
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Figure 6 Dissolution of levosimendan from modified-release capsules (F-H): ♦ = F,  = G and 
= H. Dissolution conditions: pH 7.4 and a rotation speed of 100 rpm (left) and 50 rpm (right), 
means ± SD, n = 5-6.  
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Figure 7 Dissolution of levosimendan from modified-release capsules (F-I): ♦ = F,  = G,  = H 
and  = I. Dissolution conditions: pH 5.8 and a rotation speed of 100 rpm (left) and 50 rpm (right), 
means ± SD, n = 5-6. 
Table I Pharmacokinetic parameters of modified-release capsules of levosimendan after a single 
dose of 2 mg (means ± SD, n=9).  
F G H I
Cmax (ng/ml) 64.4±26.3 55.5±23.0 45.3±20.6 36.9±18.6
Tmax (h) 1.0±0.3 1.4±0.9 1.3±0.7 2.0*±0.4
AUC0-12h (ng*h/ml) 107±49 99±47 86±39 95±47
MRT (h) 1.6±0.3 1.8±0.6 1.9±0.7 2.4*±0.3
*Statistically different, p< 0.05, compared to formulations F, G and H  
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5.1.2 Selection of dissolution method for a level A IVIVC model (I) 
In vitro dissolution at pH 7.4
At pH 7.4 and a rotation speed of 100 rpm, the discrimination ability was acceptable when 
similarity factors were compared to the variance in the Tmax and MRT of formulations F, 
G and H (Table II). However, level B or C IVIVC was not achieved with this method. 
Although the level B correlation coefficient was high (0.94), the IVIVC model was not 
reliable (Fig. 8). A pH of 7.4 with a rotation speed of 50 rpm was not acceptable because 
there was no rank order correlation between MRT and Cmax vs. dissolution rate. Neither 
level B nor level C in vitro-in vivo correlation was achieved.  
Table II Comparison of dissolution profiles to pharmacokinetic parameters and correlation 
coefficients of level B and C IVIVC.  
 pH 7.4, 
50 rpm 
pH 7.4 
100 rpm 
pH 5.8 
50 rpm 
pH 5.8 
100 rpm 
F2 vs. ANOVA - + - + 
Level C IVIVC 0.52 0.71 1* 0.85 
Level B IVIVC 0.74 0.94 0.93 0.98*
+ acceptable discrimination, - unacceptable discrimination, *statistically significant p<0.05 
In vitro dissolution at pH 5.8
Dissolution at pH 5.8 and a rotation speed of 50 rpm was over-discriminating between the 
formulations. Formulations F, G and H had dissimilar dissolution profiles, although MRT 
and Tmax values did not differ (Tables I and II). However, a level C IVIVC was achieved 
with this method. At a rotation speed of 100 rpm, formulations F, G and H had similar 
dissolution profiles, but formulation I was different. The discrimination ability of this 
dissolution method was acceptable, because Tmax and MRT values of formulation I were 
statistically significantly different from all other formulations. An acceptable level B 
IVIVC was achieved with this dissolution method (Fig. 8). 
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Figure 8 Level B IVIVC for modified-release capsules at pH 7.4 and 5.8 with a rotation speed of 
100 rpm. In vivo mean residence time (MRT) and in vitro mean dissolution time (MDT) were used 
in level B IVIVC.  
5.1.3 A stochastic level A IVIVC model for the formulation series (II) 
The averaged level A IVIVC model 
In vitro and in vivo data for formulations A to D were utilised in the construction of the 
averaged level A IVIVC model. Formulations E and F were used to test external 
predictability. The external prediction errors for Cmax were 15% and 70% for formulations 
E and F, respectively. The averaged level A IVIVC model failed for modified-release 
formulations. An alternative approach was used to obtain a level A IVIVC model.  
Modified one-compartment model parameters
A stochastic Bayesian approach was combined with a modified one-compartment model 
in order to utilise subject-specific in vivo data and to obtain predictions as probability 
distributions. Posterior distributions of modified one-compartment model parameters and 
the dissolution data were used to predict pharmacokinetic parameters and concentration 
time profiles for formulations A, B, C, D, E and F (Fig. 9, Fig. 10). The distributions for 
parameters F/Vc and k10 were quite narrow and uni-modal, indicating sufficiency of 
bioavailability data for IVIVC model construction. Parameter a was less than one because 
in vitro dissolution was faster than in vivo dissolution from the capsules. Histograms of 
distributions of the parameter tlag were concentrated differently, indicating that the use of 
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individual tlag values for each test subject was reasonable (not presented).  
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Figure 9 Histograms of marginal posterior distributions (number of simulated points =75 000) of 
parameter a, F/Vc, k10 and MAP values (vertical line).  
Predicted vs. observed time courses
Predicted concentration-time profiles of levosimendan are presented with posterior 
probability interval curves and maximum values of the posterior probability distribution 
(MAP) (Fig. 10). The observed concentration profiles of formulations A to D had a 
slightly different shape from the predicted profiles. The observed mean values were not 
always within the predicted 95% posterior probability intervals. Concentration profiles for 
formulations E and F, which were not used in the model construction, were predicted well, 
as the shapes of the observed and the predicted profiles were similar. The observed mean 
values were within the predicted 95% posterior probability intervals, except for a single 
mean value for formulation F.  
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Figure 10 Observed average values for the plasma concentration time profiles ± SEM (dots with 
error bars), predicted 95% posterior probability interval curves for average levosimendan 
concentrations in plasma (dashed lines) and MAP values (continuous line) for modified-release 
capsules A-F. 
5.2 Ranitidine as a biowaiver candidate (III) 
Pharmacokinetic properties
The oral bioavailability of ranitidine is 50-60% (Bogues et al., 1980; Garg et al., 1981; 
Chau et al., 1982; Martin et al., 1982; Garg et al., 1983). Half-life of elimination is 1.7-2.1 
h after an i.v. dose (Bogues et al., 1980; Garg et al., 1981; Mignon et al., 1982; van 
Hecken et al., 1982). The elimination rate constants are 0.3-0.4 h-1.  
The absorption of ranitidine after oral administration of different doses is linear (Mignon 
et al., 1982). Permeability across a Caco-2 cell monolayer was low, 1 to 20 x 10-7 (Gan et 
al., 1993; Walter et al., 1996; Collet et al., 1999; Lee and Thakker, 1999; Takamatsu et al., 
2001; Yazdanian et al., 2004) and it increased at lower calcium concentrations (Gan et al., 
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1993).  Colonic absorption of ranitidine is poor (Williams et al., 1992; Pithavala et al., 
1998). These in vitro and in vivo observations refer to a paracellular transport mechanism. 
The solubility was high - more than 550 mg/ml - in the pH range of 1 to 7.4. Ranitidine is 
a BCS III drug having low permeability and high solubility.  
Immediate-release dosage form performance
The effect of excipients on the in vitro permeability of BCS III drugs, including ranitidine, 
has been studied (Aungst, 2000; Rege et al., 2001). Lactose, hydroxypropylmethyl 
cellulose, docusate sodium, ethylene diamine tetracetic acid (EDTA), propylene glycol 
and polyethylene glycol (PEG) 400 did not affect the Caco-2 permeability of ranitidine. 
Some other excipients, such as sodium lauryl sulphate, sodium caprate, deoxycholate, 
glycocholate, taurodihydrofusidate and palmitoylcarnitine, which open tight junctions, 
may affect the absorption of drugs transported via the paracellular route. High 
concentrations of osmotically active excipients such as sodium acid pyrophosphate and 
PEG 400 may shorten the small intestinal transit time and thus reduce the bioavailability 
of ranitidine (Koch et al. 1993; Basit et al., 2002; Schulze et al., 2003). 
The dissolution of immediate-release ranitidine products is rapid, i.e. >85% dissolves in 
30 minutes when water or 0.1 N HCl is used as a dissolution medium (III, Table 3) (Polli, 
1997; Ali et al., 1998; Cappola, 2001; Yu et al., 2002). Based on similarity factors, all 
formulations did not have similar dissolution profiles. Similarity of dissolution profiles 
does not seem to be a critical factor because dissimilar but rapidly dissolving products 
were bioequivalent (Piscitelli et al., 1995; Polli, 1997). Simulation studies of ranitidine 
and atenolol, also a BCS III drug, showed that solid dosage forms were bioequivalent with 
oral solution if more than 85% dissolved in 1.5 hours (Kaus et al., 1999). In this study less 
than 20% differences in Cmax and AUC were accepted to prove bioequivalency. 
Simulations are supported by an experimental in vivo study in which immediate-release 
tablets of metformin, also a BCS III drug with a paracellular transport mechanism, were 
shown to have absorption similar to modified-release tablets (Balan et al., 2001; Cheng et 
al., 2004). More than 85% was dissolved in 2 hours from modified-release formulations. 
  40
5.3 Evaluation of bioequivalence risks and BCS biowaivers by 
pharmacokinetic modelling (IV) 
Rapid in vivo dissolution (Kd = 4 h-1)
Less than 10% differences in Cmax and AUC values were obtained in the simulations when 
solid dosage forms (Kd = 4 h-1) were compared to oral solution (Fig. 11). Cmax ratios of 
BCS III drugs were closer to 1.0 than the Cmax ratios of BCS I drugs, although only BCS I 
are currently accepted for biowaivers.  
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Figure 11 Cmax ratios (Cmax tablet/Cmax oral solution) of BCS I and III drugs in single unit formulation 
with an average gastric emptying rate. Absorption rates of 1.2-8 h-1 correspond to high 
permeability and 0.1-0.8 h-1 to low permeability compounds. 
BCS I (Kd = 2 h-1)
The rates of drug absorption and elimination affected the relative differences between the 
Cmax values of solid dosage forms and oral solution (Fig. 12). As the absorption and 
elimination rates increased, Cmax values for the oral dosage form deviated increasingly 
from the values for oral solution. BCS I drugs with rapid absorption and elimination had 
more than 10% differences in Cmax values. The greatest difference, 25%, was observed 
with a single unit formulation when gastric emptying was slow. In contrast, the Cmax ratio 
was nearly constant (0.95), and independent of the absorption rate, formulation and 
physiology related variables when the elimination rate constant was less than 0.2 h-1. BCS 
I drugs in a single unit formulation were more sensitive to gastric emptying rate 
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differences than multiple unit formulations. AUC values had less than 5% differences at 
all gastric emptying rates and with both formulation types. AUC was dependent only on 
absorption rate, and differences between solid dosage forms and oral solution slightly 
increased when absorption rate decreased.  
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Figure 12 Cmax ratios (Cmax tablet/Cmax oral solution) of BCS I drugs in multiple and single unit 
formulations with an average gastric emptying rate. Absorption rates of 1.2-8 h-1 correspond to 
high permeability compounds. 
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Figure 13 Cmax ratios (Cmax tablet/Cmax oral solution) of BCS III drugs in multiple and single unit 
formulations with an average gastric emptying rate. Absorption rates of 0.8-0.1 h-1 correspond to 
low permeability compounds. 
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BCS III (Kd = 2 h-1)
BCS III drugs were less sensitive to dissolution rate, gastric emptying and formulation 
type differences than BCS I drugs. Observed differences in AUC and Cmax values were 
less than 10% and thus all BCS III drugs fulfil the biowaiver criteria (Fig. 13).  
BCS II and IV drugs (Kd = 2 h-1)
Solubility in the stomach, formulation type and gastric emptying rates were all critical 
factors for Cmax differences of BCS II and IV drugs. In these two classes, clear and general 
trends in Cmax were not seen and some biowaivers may be found on a case by case basis.  
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6 Discussion 
6.1 Evaluation of ranitidine as a BCS biowaiver candidate (III) 
Literature data has been collected and evaluated to suggest potential BCS biowaiver 
compounds in the World Health Organisation (WHO) list of essential drugs. Our 
publication III for ranitidine is part of a series of publications organised by the Working 
Group on the Biopharmaceutical Classification System of the International Pharmaceutical 
Federation (FIP). 
Ranitidine is a BCS III drug having high solubility and low permeability. Oral drug 
absorption of different doses is linear (Mignon et al., 1982). The main absorption site is 
small intestine, and the permeability mechanism seems to be paracellular passive diffusion 
(Williams et al., 1992; Gan et al., 1993; Pithavala et al., 1998). Immediate-release 
ranitidine tablets have rapid dissolution (>85% in 30 minutes) in water and 0.1 N HCl 
(Polli, 1997; Ali et al., 1998; Cappola, 2001; Yu et al., 2002). The rate-limiting step for 
absorption of ranitidine is permeability, and minor differences in dissolution rate have no 
effect on absorption; thus, rapidly dissolving ranitidine formulations are bioequivalent 
(Piscitelli et al., 1995; Polli, 1997). Simulation results for ranitidine and in vivo study 
results for metformin, also a BCS III drug, indicate that rapid dissolution is not necessary 
for bioequivalence (Kaus et al, 1999; Balan et al, 2001). In those simulations, an oral 
solution of ranitidine was predicted to be bioequivalent with a solid dosage form having 
dissolution as slow as >85% dissolved in 1.5 hours. An immediate-release metformin 
formulation had a similar in vivo input profile to that of a controlled-release formulation. 
More than 85% dissolved in 2 hours from the controlled-release formulation. The 
dissolution profile of the immediate-release metformin formulation was not presented in 
these publications. The data show that rapid dissolution or similarity of dissolution 
profiles is not a critical factor for bioequivalency of ranitidine dosage forms. Therefore, 
ranitidine immediate-release tablets can be proposed as a biowaiver candidate, although 
ranitidine is BCS III drug.  
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Our study together with the Vogelpoel et al. (2004) study of atenolol are the first in which 
a BCS III drug is proposed to be suitable for a biowaiver based on an extensive drug-
specific evaluation of data from the scientific literature. Currently, only BCS I drugs are 
accepted for biowaivers, but extension of biowaivers to the BCS III drug class has been 
discussed (Blume and Schug, 1999; Dressman et al, 2001; Yu et al, 2002).  
Dissolution test can be used as a surrogate for bioequivalence studies of ranitidine 
immediate-release products, if the effects of excipients on gastrointestinal transit and 
permeability can be excluded. Some osmotically active excipients at high concentrations 
decreased the small intestinal transit time and reduced the bioavailability of ranitidine 
(Koch et al, 1993; Basit et al., 2002; Schulze et al., 2003). However, amounts as high as 
those used in these studies (1-10 g) are not used in immediate-release formulations. More 
attention should be paid to the excipients, which may open tight junctions and may 
increase absorption of paracellularly transported drugs (Aungst, 2000; Rege et al., 2001). 
However, many commonly used excipients have no effect on in vitro Caco-2 permeability 
(Rege et al., 2001). Expertise in properties of excipients, mechanisms of transport systems 
and in vitro permeability study methods is needed when determining the effects of 
excipients on permeation of BCS III drugs like ranitidine.    
To be on the safe side when applying for a biowaiver for ranitidine, the test and reference 
formulations have to comply with the requirements for "rapidly dissolving" according to 
the FDA guidelines, i.e. not less than 85% of the labelled amount dissolving within 30 min 
in 0.1 N HCl, in pH 4.5 buffer and in pH 6.8 buffer.  
6.2 Potential use during the drug development process of the models 
developed  
The dissolution test, IVIVC and pharmacokinetic models developed here can be utilised to 
estimate oral drug absorption properties during the different phases of the drug 
development process (Fig. 14). Drug input profile and time course can be simulated and 
predicted for drugs from all BCS classes and for different dosage forms (oral solution 
controlled release formulations). Level A IVIVC models are restricted to the BCS II drugs 
and controlled release formulations.  
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In the drug discovery phase, three essential in vitro parameters - permeability, solubility 
and dissolution - can be easily used to determine BCS class and maximum absorbable 
dose. These analyses give information about the extent of absorption and the rate limiting 
step of drug absorption. However, to get more complete estimates of drug absorption, a 
dynamic pharmacokinetic simulation model, e.g. CAT, should be utilised already during 
the drug discovery phase. The in vivo input profile can be simulated when permeability, 
solubility and dissolution parameters are combined with known properties of the 
gastrointestinal tract. The most critical factors that affect drug absorption can be estimated, 
and different types of formulation strategies can be evaluated, e.g., to estimate the need for 
dissolution, solubility and/or permeability enhancers.  
Drug discovery Clinical
• Permeability
• Solubility
• Dissolution  
Non clinical
• BCS, MAD
• Rate-limiting step
for absorption 
•Simulated in vivo input  
• Nonclinical PK studies
• Dissolution
• Predicted in vivo input 
or time course in certain specie
• Simulated in vivo input in human
• IVIVC for BCS II and CR  
• PK studies
• Dissolution  
• Predicted in vivo input
or time course in human
• Level A IVIVC
for BCS II and CR
Figure 14 Simulating the rate and extent of oral drug absorption during the drug development 
process.  
In the non-clinical study phase, pharmacokinetic data from various species is available. 
Again, permeability, solubility and dissolution parameters are combined with known 
physiological properties of the gastrointestinal tracts of certain species of test animals. 
Pharmacokinetic data on the distribution and elimination phases is now available, so 
concentration profiles can be predicted. The CAT model can be connected with the one 
compartment model to describe drug elimination, or with the two compartment model to 
describe drug distribution and elimination phases. Predicted and observed input or 
concentration profiles are compared. Scaling factors between in vitro and in vivo data can 
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be determined. In order to make simulations in human more reliable, a pharmacokinetic 
model should have predictive power for some test animal species. There are differences in 
the gastrointestinal physiology in animal vs. human, and the quantities of active transport 
proteins and metabolizing enzymes may vary. Thus quantitative predictions based on non-
clinical data can not be made, but the critical factors affecting drug absorption, like low 
solubility and dissolution or low passive permeability, can be evaluated. For BCS II and 
controlled-release formulations, a level A IVIVC in some test animal species may be 
found. An IVIVC model can be utilised in formulation and dissolution method 
development. 
In the clinical study phase, the CAT model is updated with human pharmacokinetic data. 
Then the predicted and observed inputs or concentration profiles in human can be 
compared. Scaling factors between in vitro and in vivo data are determined for human. 
Depending on the properties of the drug and quality of the in vitro and in vivo data, the 
possibilities for utilisation of the CAT model differ. In the most successful case, the 
plasma drug concentration profile can be predicted based on in vitro parameters describing 
the absorption phase and in vivo parameters describing the distribution and elimination 
phases. For BCS II and controlled-release formulations, a level A IVIVC model may be 
constructed and even validated. The early and extensive use of pharmacokinetic 
simulations and IVIVC models shortens the drug development period, economises on 
resources and improves drug pharmaceutical and biopharmaceutical quality.  
Commercial pharmacokinetic modelling software
Commercial programs, e.g. IDEA and Gastroplus, can be utilised to simulate and predict 
oral drug absorption in different development phases for drug products. In silico, in vitro
and in vivo data from test animals species can be used to predict absorption properties 
(Parrot and Lavé, 2002). However, these programs are not transparent; the whole structure 
of the model and the parameter values are not available. The major aim in the simulation 
is to combine many variables that are related to gastrointestinal tract physiology and drug 
and formulation properties, and to learn which are the most critical factors affecting drug 
absorption. Only a self-constructed transparent model enables an interactive learning 
process. Stella software is user-friendly and can be used to construct compartment models 
like CAT. The Stella program used with the CAT model is easy to update with whatever 
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new data becomes available during the drug development process. 
6.2.1 The potential for utilisation of level A IVIVC models in formulation 
development (I,II) 
For BCS II drugs and for controlled release formulations, drug release is the rate-limiting 
step in absorption. Thus a relationship between in vitro dissolution and in vivo input 
should be found. The development of IVIVC models is a dynamic process that should start 
early in the development phase and continue until the drug comes to market (Fig. 15) 
(Devane, 1997). In the ideal case, level A IVIVC model development and utilisation 
should proceed as described below.  
In the first stage, prototype formulations are developed, i.e. different approaches to 
enhance drug dissolution and solubility (BCS II, IV) or to extend drug release are tested. 
Formulations can have different release mechanisms due to e.g. different compositions 
and manufacturing methods. The in vitro dissolution method should be discriminative for 
formulation variables and take into account physicochemical properties of the drug. 
Typically various dissolution media, apparatuses and agitation speeds are tested. The most 
promising prototype formulations are tested in animals and/or humans. A level A IVIVC 
model can be developed when in vivo pharmacokinetic and dissolution data is available 
for different formulations. All prototype formulations probably have different IVIVC 
models, i.e. models based on different dissolution methods and time-scale factors between 
in vitro and in vivo data. Level A IVIVC models are formulation specific and thus cannot 
be used to predict in vivo input or concentrations in plasma for formulations that are 
different from those studied in vivo. However, if two or three prototype formulations 
having the same qualitative composition have been studied, a target absorption profile 
may be achieved and a validated level A IVIVC model can be developed. Then the most 
promising formulation and dissolution method can be selected for further development. In 
the less successful case, a target absorption profile is not achieved and new formulations 
have to be developed and studied in vitro and in vivo.  
In the second stage, after prototype formulations have been developed, the batch size is 
scaled-up and formulation is optimised. To get a validated level A IVIVC model, at least 
two (three are recommended) different formulations should be studied in vivo (FDA 
guidance, 1997). The exception is formulations in which in vitro dissolution is 
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independent of dissolution test conditions e.g. pH and agitation speed. Then, one 
formulation is enough for IVIVC model development and validation. Formulations having 
in vitro dissolution that is dependent on test conditions should have the same qualitative 
composition, but the amount of rate-controlling excipients are varied. The dissolution 
method has to be sensitive to formulation-specific variables, like the amount of rate-
controlling excipient and manufacturing process variables. Formulation, process and 
dissolution method optimisation studies together with a validated level A IVIVC model 
give a good understanding of the release mechanism of formulations and the most critical 
variables affecting drug release and dissolution. In some cases, the target formulation can 
be intermediate between two formulations studied in vivo. Then the validated level A 
IVIVC model can be used for optimisation of the final formulation. Only the most 
promising formulation(s) should be studied in vivo. For the final formulation, dissolution 
specifications can be set based on the IVIVC (FDA guidance, 1997; Piscitelli and Young, 
1997).  
2. Formulation
development
1. Prototype
formulations
3. Final
formulation
• Nonclinical PK studies
• PK study 
• Level A IVIVC
• Formulation 
optimisation
• Process optimisation
• Scale-up
• PK study
• Validated
level A IVIVC
• Clinical trials
• Marketing 
authorisation
• SUPAC, variations
• Biowaiver IVIVC
Figure 15 The IVIVC model development process for BCS II drugs and controlled-release 
products during drug development.  
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In the third stage, a validated level A IVIVC model together with in vitro dissolution data 
can be used for a biowaiver when the drug product is modified. The drug product can be 
under clinical studies or already on the market. Validated level A IVIVC models guide 
formulation and manufacturing method revision, and in vivo bioequivalence studies are 
not needed in the regulatory application. 
The selection of dissolution method for a level A IVIVC (I)
The selection of a dissolution method for a level A IVIVC model is a critical step in the 
formulation development process of BCS II drugs and controlled-release formulations. To 
be successful, physicochemical, pharmaceutical, biopharmaceutical and pharmacokinetic 
properties of the drug and drug product together with gastrointestinal physiology should 
be taken into account. A pharmacokinetic simulation model may be a useful tool to 
combine information from different sources.  
Levosimendan is a BCS I drug having rapid absorption and elimination phases (Sandell et 
al., 1995; Sundberg et al., 1998). Thus, drug concentration levels in plasma will fluctuate, 
and it must be administered in an immediate-release formulation several times a day. To 
avoid this, a series of modified-release formulations were developed. The qualitative 
composition of four formulations was similar, but the amount of the rate-controlling 
excipients hydroxypropylmethylcellulose and alginic acid increased from formulations F 
to I.  
To develop a level A IVIVC for these modified-release formulations, several dissolution 
methods were tested. The rotation speed of the basket was either 50 or 100, and pH values 
of 5.8 and 7.4 were selected because they are around the pKa value of levosimendan 
(6.26) and they represented pH values of the upper (pH 5.8) and lower parts (pH 7.4) of 
the intestine. Bioavailability and dissolution data was used to study in vitro-in vivo
relationships. Level B and C IVIVC models were generated and similarity factors of the 
dissolution profiles were compared to the differences in pharmacokinetic parameters using 
ANOVA. Based on the level B and C IVIVC models, the pH 5.8 dissolution methods were 
promising. A rotation speed of 100 rpm was the best choice and had adequate 
discriminating power. A rotation speed of 50 rpm was too discriminating, because even 
formulations without statistically significant differences in Tmax and MRT values showed 
dissimilar dissolution profiles. Dissolution at pH 7.4 with a rotation speed of 100 had 
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acceptable discrimination ability, but level B and C IVIVCs failed. Hence, for further 
development, dissolution conditions were chosen to be pH 5.8 and a rotation speed of 100 
rpm. The dissolution rate of levosimendan from modified-release formulations is only 
slightly extended. Most likely the main absorption site is the upper part of the small 
intestine, and pH 5.8 mimicked in vivo dissolution conditions better than pH 7.4.   
This study suggests for the first time that the comparison of similarity factors of 
dissolution profiles vs. differences in pharmacokinetic parameters is useful as a criterion 
in selection of a dissolution method for level A IVIVC models. Typically, level B and C 
IVIVC models have been used for selection of dissolution methods (Lake et al., 1999). In 
our case, level B and C IVIVC alone could lead to selection of an over-discriminating 
dissolution method. At pH 5.8, both rotation speeds, 50 and 100 rpm, had acceptable 
(level B or C) IVIVC, but the lower speed was over-discriminating, whereas the higher 
speed had an acceptable discrimination ability. An over-discriminating dissolution method 
as a quality control tool could lead to unnecessary rejection of batches during stability 
studies. It could also lead to failure of such modifications as scale-up of clinical batches, 
changes to the formulation and changes to the manufacturing method. The development of 
a level A IVIVC model may also fail if the dissolution method does not have proper 
discrimination ability. Thus, allocation of resources for dissolution method development 
in the early drug development phase is justified in order to avoid unnecessary formulation 
development efforts and in vivo studies.  
A level A IVIVC model with a Bayesian approach to formulation series (II)
As with dissolution method selection, the construction of an in vitro-in vivo relationship 
may be challenging. Especially with high variability drugs, level A IVIVC models may 
fail. This variability may be due to formulation effects and differences in individual 
subjects. In many cases, the subject related variability is much greater than the variability 
between formulations (Mauger and Chinchilli, 1997). In vitro dissolution data shows only 
formulation differences. If the drug substance and formulations have high intra- and/or 
inter-subject variability, many subjects are needed for in vivo studies; otherwise, level A 
IVIVC may not be obtained. In the early phase of drug development, it is difficult to 
estimate what a sufficient sample size would be, since in vivo data of controlled-release 
formulations is not yet available. Resources and time would be saved, and the necessity 
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for healthy volunteers would be minimised, if subject-specific in vivo data could be 
utilised effectively in the level A IVIVC model development.  
The in vivo data of levosimendan modified-release capsules had high variability and only 
nine subjects were involved in the study. With this data, the averaged level A IVIVC 
model failed. External prediction errors for Cmax were 15 and 70% for formulations E and 
F. The current maximum prediction error allowed according to regulatory guidances is 
10% (FDA guidance, 1997, EMEA, 2000). With these challenging data, a stochastic 
approach was adopted in level A IVIVC model development. A Bayesian approach was 
integrated with the level A IVIVC model. The in vitro-in vivo relationship was described 
with modified one-compartment model parameters. The Bayesian approach consisted of 
prior data of model parameters and likelihood function, which defined the connection 
between in vitro and in vivo data a with modified one-compartment model. As a result of 
the simulations, posterior distribution of model parameters, pharmacokinetic parameters 
and time courses were obtained. Subject specific in vivo data was utilised and thus all 
predictions were found as probability distributions. Posterior distributions represent 
uncertainty and variability related to the data and the suitability of the modified one-
compartment model. The level A Bayesian IVIVC model had good external predictability: 
the observed mean in vivo concentrations were mostly within the predicted 95% posterior 
probability intervals. Uni-modality and narrow distributions of modified one-compartment 
model parameters support the reliability of the level A IVIVC model. The constructed 
model enables prediction of the levosimendan concentration profiles in plasma based on in 
vitro dissolution data alone. The level A IVIVC model with Bayesian approach is a useful 
tool in the development of levosimendan modified-release formulations.  
In general, the Bayesian level A IVIVC models can be utilised for product development 
purposes if the rate-limiting step for absorption is the dissolution phase. The one-
compartment model as a level A IVIVC model with the Bayesian approach requires the 
same AUC values for all formulations used in the level A IVIVC model development, 
because differences in AUC can not be predicted with this type of model. AUC values are 
the same for all formulations when the drug is absorbed to the same extent from all of 
them. Formulations can have effect on the extent of absorption when they have different 
absorption windows, e.g. some formulations dissolve already in the small intestine and 
others have slower dissolution, in which part of the drug is dissolved and absorbed in the 
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colon. In this case, AUC values for formulations can differ. In our study, the AUC of 
levosimendan modified-release formulations was not dependent on the formulations.  
In our study, a modified one-compartment model with a Bayesian approach was used in 
direct convolution. Thus, an oral solution, i.v., bolus or immediate-release dosage form is 
not needed as a reference, as it is in many level A IVIVC models published earlier 
(Eddington et al., 1998; Modi et al., 2000; Balan et al., 2001; O’Hara et al., 2001; Pitsiu et 
al., 2001; Sirisuth et al., 2002a). Our study is the first in which a stochastic IVIVC model 
was developed and validated for a formulation series.  
To use the stochastic level A IVIVC model for regulatory purposes, new validity criteria 
are needed. Current criteria are based on single values, and as such they are intended for 
averaged IVIVC models (FDA guidance, 1997, EMEA, 2000). To set up validity criteria 
for stochastic IVIVC models, several different kinds of drugs and products should be 
studied. To generate a level A IVIVC model with the Bayesian approach, high-level 
mathematical skills are needed. New user-friendly software would enable extended 
utilisation of stochastic IVIVC models. More efficient utilisation of in vivo bioavailability 
data and stochastic IVIVC models would save time and costs, and reduce the number of 
healthy volunteers needed during new drug development. A stochastic level A IVIVC 
model may be achieved even in cases where averaged IVIVC models have failed.  
6.2.2 Simulation studies for proposing biowaver candidates and estimating risks 
related to bioequivalence (IV) 
A dynamic simulation model, in which time dependent drug substance, drug product and 
gastrointestinal tract physiology-related variables can be easily taken into account, is a 
useful tool to estimate risks related to test and reference product bioequivalence and to 
suggest biowaiver candidates. Utilisation of a transparent pharmacokinetic simulation 
model, which covers a wide and realistic range of biopharmaceutical and pharmacokinetic 
variables, including elimination, has not been reported previously in the context of 
bioequivalence and biowaivers. In our simulation studies, an oral solution was compared 
to the solid dosage form. The effects of absorption and elimination rates on Cmax and AUC 
differences were studied, as well as different formulation types and variability in gastric 
emptying rates.  
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We considered a 10% difference in AUC and Cmax as the limit for low risk of failure in 
bioequivalence studies. In the current bioequivalence guidelines, the acceptable difference 
is 20% with 90% confidence intervals. The 10% difference in our study represents drug 
product-related effects i.e. the effect of dissolution rate and formulation type together with 
intra- and inter-individual variability related to gastric emptying. Variability related to 
permeability, distribution and elimination phases of drugs, and gastrointestinal tract 
physiology factors like small intestine transit time or variable pH conditions in the 
stomach and intestine was not taken into account. However, transit in the small intestine 
does not show high intra-individual variability and it is not dependent on formulation 
types or nutrition status (Christensen et al. 1985; Davis et al. 1986; Coupe et al. 1991; 
Wilding et al. 2003). Variable pH conditions are not critical for high solubility (BCS I and 
III) drugs.  
A dynamic pharmacokinetic model has not been previously used to estimate risks that are 
related to biowaiver decisions. The basic idea of biowaiver eligible compounds is that the 
rate and the extent of oral drug absorption should not be dependent on dissolution and/or 
gastrointestinal transit time (FDA guidance, 2000). Thus, the oral dosage forms should 
behave like an oral solution and the gastric emptying of the dissolved drug is the rate-
limiting step for absorption. Based on that, Cmax and AUC values for the solid dosage form 
were compared to values for oral solution. A dissolution rate constant of 2 h-1 (>85% 
dissolved in 60 min) and the current BCS biowaiver requirement for rapid in vitro
dissolution (4 h-1, >85% dissolved in 30 min) were both studied. It is important to study 
the slower dissolution rate because in vivo dissolution in the stomach is, in many cases, 
probably slower than in vitro dissolution. In vitro dissolution tests are carried out with 
high rotation speeds of basket or paddle (50-100 rpm), whereas in the fasting stomach 
there are long periods of little or no motor activity (Dressman et al., 1998). A high volume 
of liquid (500-900 ml) is used for in vitro tests as compared to the conditions in stomach, 
where liquid volume is initially about 250 ml, but decreases rapidly to 50 ml (Wilson and 
Washington, 1989; Schiller et al., 2005). Based on these physiological facts, we assumed 
that in vivo dissolution is slower than in vitro dissolution. Our study is the first to evaluate 
the influences of formulation types, physiology of the gastrointestinal tract and drug 
properties including elimination against the current biowaiver criteria.  
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BCS I drugs
Some of the BCS I drugs were good biowaiver candidates, but a notable portion were not 
(Fig. 16). Interestingly, Cmax was highly dependent on both absorption and elimination 
rates. The combination of rapid absorption and elimination resulted in 10-25% differences 
in Cmax values and such compounds were also sensitive to differences in formulation type 
and gastric emptying rates. These types of BCS I drugs have a high risk of failure in 
bioequivalency studies and thus in vivo studies should be carried out. In contrast, for BCS 
I drugs with elimination rate constants of < 0.2 h-1, the differences in Cmax and AUC 
values with both formulation types and with all gastric emptying rates were less than 5%. 
These drugs have low risk of failure in bioequivalence studies and they are good 
candidates for biowaivers. Based on our simulations, the rate of drug elimination should 
also be taken into account. Follow-up simulations support our conclusions (Fagerholm, 
2007). Very high permeability and a short half-life caused difference in Cmax and AUC 
when dissolution rate were reduced from 4 h-1 to 1 h-1.  
BCS I BCS IIIBCS II BCS IV
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and elimination
rate
Regulatory
strategy
Rapid
absorption
and elimination
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BCS
biowaiver
No Yes
BE
studies
Figure 16 Utilization of dynamic pharmacokinetic modelling in selection of regulatory strategies. 
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Acidic BCS II drugs
The Cmax and AUC values of a considerable number of acidic BCS II drugs are dependent 
on absorption and elimination rates as well as solubility and dissolution (Fig. 16). Thus, 
the risks related to bioequivalence should be evaluated on a case-by-case basis for this 
class of drugs, so that drug products which have low risks of failure in bioequivalence 
studies can be identified. Dissolution is the rate-limiting step for many BCS II drugs. They 
have a higher risk of failure in bioequivalence studies, but in those cases a level A IVIVC 
may be found and in vitro dissolution may be used as a surrogate for in vivo
bioequivalency studies.  
BCS III drugs
Based on current regulatory guidelines, BCS III drugs are not accepted for biowaivers. 
However, this class has been proposed in many publications as appropriate for biowaivers 
if the effects of excipients on the gastrointestinal transit time and permeability can be 
excluded (Blume, Schug 1999; Yu et al. 2002; Cheng et al. 2004; Vogelpoel et al. 2004; 
Jantratid et al., 2006). BCS III drugs have low permeability, which, rather than 
dissolution, is the limiting factor for absorption. This was clearly seen in a bioavailability 
study of cimetidine immediate-release and controlled-release formulations (Jantratid et al., 
2006). Permeability was the rate-limiting step for in vivo absorption even when more than 
85% of the drug dissolved in 90 minutes. In other studies, three ranitidine immediate-
release tablets were found to be bioequivalent when more than 85% was dissolved in 30 
minutes; however, dissolution profiles were dissimilar (Piscitelli et al., 1995; Polli, 1997). 
The BCS III drug metformin had similar absorption from immediate-release and 
controlled-release formulations (Balan et al., 2001). Controlled-release formulations had 
quite slow dissolution. More than 85% was dissolved in 180 minutes. Thus even major 
changes in dissolution rate do not have an effect on Cmax or AUC. In many publications, 
BCS III drugs have been suggested for biowaivers if more than 85% of the drug dissolves 
in 15 minutes (Yu et al., 2002; Polli et al., 2004; WHO, 2006). Based on a few in vivo
studies of class III drugs and our simulations, this dissolution limit is conservative and, at 
the least, a limit of more than 85% dissolved in 30 minutes would be sufficient to 
guarantee bioequivalency. In our simulations, differences in Cmax and AUC of BCS III 
drugs were less than 10% when more than 85% was dissolved in 30 or 60 minutes. 
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However, slower dissolution rates were not studied.  
The effects of excipients on absorption and transport mechanism of BCS III drugs should 
be evaluated carefully before a biowaiver is applied for. Some excipients may open tight 
junctions and increase absorption of paracellularly transported drugs like ranitidine 
(Aungst, 2000). One reason for poor absorption can be drug active efflux to the gut lumen, 
and since some excipients can be substrates or inhibitors of the efflux proteins, they may 
increase drug absorption. To be a BCS III biowaiver candidate, the main absorption 
mechanism should be passive diffusion. Thus, excipients affecting efflux and transport 
proteins are not of concern in the context of BCS III biowaivers.  
BCS III drugs were less sensitive to changes in formulation type and gastric emptying 
rates than BCS I drugs with rapid or rather rapid absorption and elimination. BSC III 
drugs are also less sensitive to food effects than BCS I drugs (Lennernäs and 
Abrahamsson, 2005). The ability of food to increase solubilisation does not increase oral 
absorption of BCS III drugs, as it does with low solubility drugs. Small intestinal transit 
time is a critical factor for extent of absorption of BCS III drugs. However, food 
administration does not have an effect on small intestinal transit time (Davis et al. 1986). 
It can be concluded that BCS III drugs are not sensitive to physiological factors (gastric 
emptying rates), food effects or minor changes in drug product (formulation type, 
dissolution). 
Acidic BCS IV drugs
Some BCS IV drugs may be biowaiver candidates but a significant part would not be (Fig. 
16). The rate limiting step for absorption is a complex combination of permeability, 
solubility and dissolution properties. Thus, in many cases in vivo bioequivalency studies 
are needed. 
Bioequivalence study design
A pharmacokinetic simulation model can be used to estimate risks related to in vivo
bioequivalency studies. Simulations and predictions can guide bioequivalency study 
design. Product sensitivity to dissolution rate differences depends on absorption and 
elimination rates. Cmax and AUC ratios for test vs. reference product can be simulated and, 
   57
based on that, sample size needed for a bioequivalency study can be estimated. BCS I and 
II drugs with rapid elimination are the most sensitive to dissolution rate differences. Thus, 
test and reference product should have similar dissolution profiles in the pH range 
covering the gastrointestinal tract, and perhaps more subjects are needed in bioequivalency 
studies than for BCS III drugs. For BCS III drugs, dissolution profiles of test and reference 
do not have to be similar and fewer subjects may be needed for in vivo studies than for 
rapidly eliminated BCS I and II drugs. However, drugs from any BCS class can have high 
variability in pharmacokinetics. Saturable active transport mechanisms may be involved in 
drug absorption or metabolism, drug dissolution or solubility of low solubility drugs may 
be highly dependent on pH; and differences in gastric emptying rates cause variability to 
the rate and extent of oral absorption. Any of these factors may lead to a larger number of 
subjects being needed in bioequivalency studies.  
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7 Conclusions 
Pharmacokinetic models were constructed for bioequivalence risk analysis, biowaiver 
selection and to asses IVIVC properties. These models are potential tools for formulation 
development and regulatory applications. The specific results and conclusions are: 
1. A predictive and discriminative dissolution method was developed for levosimendan 
modified-release capsules at a level A IVIVC.  
2. A predictive stochastic IVIVC modelling method was developed. The model predicted 
the concentration profiles of a levosimendan modified-release formulation series as 
probability distributions based on in vitro dissolution data and subject-specific in vivo
data. 
3. Ranitidine, a BCS III compound, is proposed as a biowaiver candidate, because 
differences in its dissolution rate do not cause risks of bioinequivalence.  
4. A pharmacokinetic simulation model is a valuable tool to estimate risks of 
bioinequivalence and to evaluate potential biowaiver candidate drugs. 
5. The simulations suggest that the BCS III drugs have a lower risk of bioinequivalence 
and they are in general more suitable for biowaivers than BCS I drugs. A short half-
life of drug elimination and/or a rapid rate of absorption increase the risk of 
bioinequivalence for BCS I drugs. BCS I drugs were also more sensitive to gastric 
emptying rate and formulation type differences than BCS III drugs.  
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